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Abstract
Ischemia-reperfusion injury (IRI) contributes to reduced long term organ transplant
survival. IRI is a complex process related to multiple mechanisms including regulated
forms of cell death such as apoptosis and necroptosis. We have previously shown that
preventing necroptosis by genetic elimination of the key molecule (RIPK3) or apoptosis
inhibition through caspase-8 silencing are of benefit in kidney IRI. As these pathways of
regulated cell death are unique, we tested the hypothesis that deletion of both RIPK3 and
caspase-8 activity in kidneys would synergistically improve renal IRI, compared to
inhibition of individual pathways. Interestingly we found that IRI was not improved in
vivo using RIPK3/caspase-8 null (DKO) mice. In vitro testing of renal tubular epithelial
cells (TEC) from DKO kidneys showed enhanced death following exposure to IFN-γ +
IL-1β suggesting enhanced activation of an intrinsic apoptosis pathway. Indeed enhanced
caspase-9 and -3 activation was observed, as well as death of DKO TEC was inhibited by
the BAX inhibiting peptide V5 (BIP). Finally, murine cytomegalovirus (MCMV)
infection, which can block intrinsic apoptosis, was able to abrogate death in DKO TEC.
In the absence of cell death, cytokine exposed DKO TEC showed increased expression of
pro-inflammatory chemokines. Collectively these results indicate that cell death pathways
are complex and counterbalanced. In the absence of RIPK3 and caspase-8, intrinsic
apoptosis and chemokine expression is up-regulated in TEC which may account for the
absence of the expected benefit from the loss of both apoptosis and necroptosis. These
results highlight the complex biology that results from targeted perturbations of death
pathways in TEC and suggest that the inhibition of multiple forms of cell death will
likely be required to maximize clinical benefit in IRI and transplants.
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Chapter 1

1

Introduction

1.1 Current situation and challenges of kidney allograft
transplantation
Kidney transplantation and dialysis, collectively known as renal replacement therapies
(RRT), are the only two treatment options after end-stage kidney failure occurs and organ
damage is irremediable. While dialysis remains a common treatment option for the
majority of patients1, kidney transplantation is both cost-effective and preferred therapy
as it consistently improves survival in patients when compared to those on dialysis2-4. It is
known since 2005 that high blood pressure, diabetes mellitus, glomerulonephritis, and
hypertension are factors that contributed to the development of chronic kidney disease
(CKD)5. Typical signs of CKD are related to loss of kidney function and include loss of
water, acid-base, and electrolyte homeostasis, as well as loss of growth factors such as
erythropoietin (EPO). CKD is categorized into five stages based on the level of kidney
function, severity of the damage, symptoms, and glomerular filtration rate (GFR) (Figure
1). Normally, CKD gradually and steadily progresses over these stages, taking years at
times. However, CKD can accelerate at times, leading to more acute loss of kidney
function requiring emergency dialysis. Combination of proper diet and the use of
medications to treat blood pressure and other factors that injure kidneys can significantly
attenuate the progress of CKD during its early stages. Indeed not every patient fully goes
through every stage of CKD. Once CKD reaches Stage 5, also known as end-stage renal
disease (ESRD), kidneys are considered to have failed as their function drops below 15%.
ESRD patients require RRTs, as onset of complications can ultimately cause death6,7.
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Kidney transplantation offers the best chance of survival in ESRD patients, but it poses
variety of complications8-10, particularly with insufficient numbers of donor organ and the
use of deceased donor organs. Storage of organs and use of more marginal donors with
underlying medical conditions can lead to reduced organ viability and contribute to
increased rejection. Graft survival depends on multiple factors, including the age and
health conditions of both the donor and the recipient, use of live or deceased donors, cold
storage and ischemic times, development of acute tubular necrosis (ATN), and amount of
fibrosis11,12. To counter rejection post-transplantation, immunosuppressive therapies are
provided, which have side effects including predisposing recipients to some forms of
cancer and opportunistic infections11. Immunological complications include allo-rejection
and in some transplant situations Graft vs. Host Disease (GVHD) further reduce graft and
even recipient survival. The total injury of transplanted kidneys extends from early injury
that invariably is associated with the removal and storage of kidneys from the donor, to
the complex injury that follows re-establishing the blood supply, namely ischemiareperfusion injury (IRI), to acute and chronic immunological rejection. Interventions at
any of these levels may improve transplant organ survival but most current efforts have
relied almost entirely on the prevention of immune rejection. Therefore, to maximize
kidney graft survival, it is imperative to further study and understand the early
mechanisms that underlie initial graft injury. This is even more important considering the
irreconcilable disparities between the rapidly increasing demand of kidneys and growing
shortage of available donor organs13,14.
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Five Stages of Chronic Kidney Disease
Stage

Kidney
function

Stage 1 >90%
Stage 2 60~89%
Stage 3 30~59%
Stage 4 15~29%
Stage 5 <15%

!

Description of
damage

Symptoms

Minor kidney
damage with
normal function
Mild damage and
decreased function

Normal urea and
creatinine level

Slightly elevated
urea and
creatinine level
Mild to moderate
Onset of fatigue
kidney damage
and itching
Severe damage and Tiredness, loss of
poor function
appetite
Kidney failure and High urea and
onset of ESRD
creatinine level,
insomnia,
frequent vomiting

Glomerular
filtration rate
90mL/min
60~89mL/min
30~59mL/min
15~29mL/min
<15mL/min
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Figure 1. Characteristics of CKD by stages
CKD is grouped into five different stages, each categorized by level of kidney function,
severity of damage, symptoms, and glomerular filtration rate. CKD starts off from
Stage 1, and progressively worsens as the stage level increases. Once Stage 5 is
reached, ESRD occurs and RRTs are needed to keep the patients alive.
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1.2 Anatomy of the kidney and immunophysiology of
tubular epithelial cells (TEC)
Kidneys are a pair of ‘bean-shaped’ organs with parenchymal cells encased by a renal
capsule composed of fibrous tissue. The structure of kidneys maintains a concave and
convex shape. Beside the concave surface on the medial border of the kidney, lies the
renal pedicle, which consists of a structure containing blood vessels, nerves, and the
ureter. The renal parenchyma can be divided into two distinct anatomical regions: the
superficial renal cortex and the deep renal medulla. Spanning both the cortex and medulla
are ‘nephrons’, the basic functional unit of the kidney. Nephrons jointly form into renal
columns that display a pyramid-like appearance. Each nephron contains proximal and
distal tubules that are aligned by individual tubular epithelial cells (TEC) that are the
kidney’s most metabolically active and functional cells. TEC possess both apical and
basolateral aspects as polarity (an ‘up’ and ‘down’ of the cell) which is a unique
characteristic of epithelial cells (Figure 2). These cells are also key participants during
graft recognition by host immune cells and kidney rejection. TEC comprise more than
75% of the renal parenchyma, and are particularly susceptible to damage caused by
reactive oxygen species (ROS), nitric oxide, pro-inflammatory cytokines, and cellmediated killing that are the primary mechanisms by which ischemia reperfusion injury
(IRI) occurs, as well as later by immune rejection15-17. With the ability to repair injury
during the IRI18, the viability of TEC and other parenchymal cells primarily influence the
outcome of both short- and long-term kidney allograft survival19. As a result, TEC play a
pivotal role in modulating alloimmune responses post-renal transplantation since they act
as the first barrier between the recipient and the graft survival.
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Figure 2. Anatomy and morphology of kidney and TEC
The kidney possesses a concave and convex shape. The kidney is divided into two
main sections, namely the outer cortical region and the inner medulla region. The
outer cortical region consists of renal columns and renal pyramids composed of
nephrons, which are the fundamental functional units of the kidney. TEC reside in
proximal and distal tubules of the nephrons, where they actively perform filtration and
reabsorption. After transplantation, the initial severe damage to TEC during IRI leads
to inflammation, dysfunction of cells, and organ failure.
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1.3 Mechanisms of IRI and regulation of cell death in acute
renal allograft rejection
Renal allografts undergo injury and damage induced by many different factors20,21, but the
earliest is IRI. IRI consists of inevitable and diverse inflammatory responses elicited by
the interaction of recipient cells with factors and cells within the donor organ, and occurs
during the early phase of renal transplantation22. IRI is responsible for causing graft
dysfunction and promoting rejection23, but it is important that there are diverse forms of
IRI related kidney injury including drugs, sepsis, cardiac injury and others that lead to
acute renal failure (ARF), as these can have mortality rates that reach 50% or higher24.
During renal ischemia, the blood supply to the kidney tissues becomes severely restricted,
or nonexistent. This results in depletion of cellular oxygen and glucose storage required
for cell survival and metabolism25. Absence of oxygen and nutrients during the ischemic
period pre-disposes the renal tissues to reperfusion damage26, which occurs after the
blood supply returns to the organ. In the case of transplantation, this is with the
establishment of the anastomoses. The majority of damage actually results from the
restoration of circulation, as it results in a rapid and sudden increase in organ source
generation of reactive oxygen species (ROS)27, up-regulation of inflammatory cytokines
and chemokines28,29, and recruitment of immune cells30,31. During renal IRI, complex
interactions of innate32,33, humoral34-36 and cell-mediated37-39 immune responses accelerate
and amplify the widespread injury of the donor organ and this contributes to rejection by
the signaling of adaptive immune responses by innate inflammation. Both innate and
adaptive immune responses are capable of inflicting heavy damages on the graft
independently and collectively through cross-talk and activation.
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The innate immune system usually contributes first to IRI. Neutrophil accumulation40,41,
Toll like receptor (TLR) signaling42, natural killer (NK) cell activation43, and complement
pathways44 represent the most common innate immune responses during IRI45. These are
often cross-linked in nature46. The influx of polymorphonuclear (PMN) neutrophils takes
place during IRI and these early cells mostly localize into peritubular capillaries, tubular
lumens, vascular endothelium, and the insterstitium47. Upon entering the renal graft, PMN
migrate into the microvasculature48 and release oxygen-free radicals and proteases49.
They also contain high levels of three pro-inflammatory cytokines in TNFα, IFN- γ, and
IL-647, consistent with their highly inflammatory capacity. Release of these cytokines as
well as neutrophil extracellular traps (NET) composed of toxic intracellular contents
triggers a ‘cascade’ of inflammation resulting in the death of TEC and other parenchymal
cells50, a process known as NETosis51. Dying renal cells often undergo necrosis26 and
consequently leak intracellular contents that act as danger-associated molecular patterns
(DAMP), namely histone proteins52 and high-mobility group box-1 (HMGB-1)53. These
DAMPs can bind TLRs of neighbouring cells. TLR 252,54, 455,56, and receptor for
advanced glycan end-products (RAGE)57 play significant roles in triggering proinflammatory pathways such as NF-κB in activated cells. HMGB-1 can also up-regulate
IFN- γ production from macrophage-activated NK cells58, further driving inflammatory
response. DAMPs binding to TLRs and other receptors of the innate immune system
activates NF-κB signalling and results in increased production and release of
cytokines59,60 in many cells including monocytes which stimulates of NADPH oxidase
and consequent release of ROS from neutrophils61,62.
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DAMPs are also capable of activating complement systems through pattern recognition
receptors (PRR). Alternative and mannose-lectin pathways are mainly associated with
renal IRI. Several murine renal IRI models have shown alternative pathway activation
leads to massive C3 production from activated TEC after reperfusion63. The resultant upregulation of C3a subunit plays a crucial role in CXC chemokine production64. C3 also
mediates T cell response65 and silencing C3 gene attenuates IRI66, further displaying the
detrimental effect of alternative complement pathway activation in IRI. The Mannoselectin pathway is also involved in IRI67, and is activated via recognition of endogenous
DAMPs presented on receptors of TEC68. Both C5a44 and C5b69 are key players in this
injury. Accumulation of the C5b-9 membrane attack complexes on TEC stimulates the
production of TNFα and IL-6, and demonstrates the role of complement pathways via
endogenous danger molecules in outcome of renal grafts following ischemia.
‘Humoral’ immune responses during IRI have not been studied extensively, but limited
knowledge points to their involvement in IRI. Naive B cells that infiltrate kidneys during
IRI become activated and differentiate into antibody producing plasma B cells70,
hindering injury repair and augmenting tubular atrophy71. Importantly, B cell deficiency
in a murine model exhibited better renal function and reduced acute tubular necrosis in
IRI, highlighting the poorly understood contribution of B cells to IRI72. Humoral
immunity appears to have a larger role in ‘chronic rejection’, as alloantibody can be
elicited in the graft in late stages of injury73.
Cell-mediated responses (CMR) in acute injury following ischemia is highlighted by the
presence of infiltrating leukocytes74 which can induce death43 in renal parenchymal cells
and promote expressions of diverse pro-inflammatory chemokines and cytokines29,30,75,76.
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Cells from both innate and adaptive immune compartments participate in CMR
associated with IRI, as activated CD4+ Helper T cells77,78, CD8+ Cytotoxic T cells38, NK
cells43,79, NKT cells80, macrophages81,82, and antibody-secreting plasma B cells72 have all
been shown to participate. These effector cells infiltrate into the renal parenchyma and
attack the graft in numerous ways. In the current model of CMR and IRI, there are two
main aspects by which immune cells injure the graft, namely by direct or indirect killing
(Figure 3).
In the direct killing model, mature and fully allo-activated T cells bind to TEC and induce
their death. During ARF, CD4+ T helper cells are considered to be one of the main
effectors due to their ability to infiltrate into the kidney quickly i.e. within 4 hours49,83 and
induce apoptosis of TEC through the FAS-FASL pathway84,85. This has been
characterized as the “hit-and-run”phenomenon86. Consistent with this, blocking FASL on
leukocytes significantly attenuates IRI84, thus supporting the importance of FAS-FASL
interactions in ARF. Cytotoxic CD 8+ T cells also damage the graft by physically
adhering to kidney cells and secreting perforin and granzyme87, inducing death by
apoptosis43. In ARF, FAS-FASL and perforin/granzyme pathways are the two best
characterized TEC death inducers88,89. It should be noted that FAS and FASL are also
expressed on the surface of TEC88,90, and not restricted to infiltrating immune cells
(Figure 3). This allows TEC to induce self-injury and apoptosis to contribute to IRI91, a
phenomenon known as “fratricide,” or “self-tubulocide” (Figure 3). Further study into the
role of FAS-FASL in TEC has shown that polymorphisms in Fas are important in longterm graft survival92.
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In indirect killing, renal cells are exposed to pro-inflammatory chemokines and cytokines
secreted by infiltrating immune cells during IRI. Two of the best-characterized
chemokines involved in renal IRI are monocyte chemotactic protein-1 (MCP-1) and
Regulated on Activation Normal T cell Expressed and Secreted (RANTES). MCP-1 acts
as a chemotactic protein during IRI as it recruits monocytes30, macrophages93, dendritic
cells31 to the graft. Once recruited, these immune effectors secrete other pro-inflammatory
chemokines94 and cytokines31, resulting in amplified activation of inflammation and
infiltration by immune cells. Studies have shown that truncation of secreted MCP-1
significantly attenuated immune cell infiltration and tubular necrosis95, thus supporting
the involvement of MCP-1 in IRI. RANTES is secreted by TEC as well as infiltrating
macrophages96,97 and contribute to inflammation and TEC death in renal IRI98. RANTES
recruits T cells99, basophils100, and eosinophils101 into the injury site of the graft. With the
combination of IL-2 and IFN- γ secreted from surrounding cells, RANTES induces
proliferation and activation of chemokine-activated killer (CHAK) cells from the NK cell
population102,103, which enhances apoptosis in TEC and compromises the graft survival.
Release of early-phase pro-inflammatory cytokines and chemokines from both immune
cells and TEC further augments acute kidney damage. TEC damaged by ROS production
secrete DAMPs which in turn activate nearby infiltrating macrophages and triggers the
secretion of IL-6 104. IL-6 is a pro-inflammatory acute phase response cytokine. Its
maximal expression and secretion occurs as early as 4 hours after IRI29,105. IL-6 secretion
results in stimulation of production and infiltration of neutrophils into peritubular
capillaries and the inner cortex of kidney grafts106. Genetic deletion of IL-6 and its
receptor results in significant improvement of renal function and reduction in
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inflammation105,106, which signifies the potential maladaptive and harmful role of IL-6
during IRI107. Thus, during ARF, the combination of diverse recipient immune responses
mediates TEC death and inflammation, which result in significant organ injury and
promotes rejection. Since IRI-mediated ARF coordinates this complex set of responses,
further studies may determine potential pathways that can be targeted to limit injury and
promote long-term organ survival.
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Figure 3. Characteristics of CMR during IRI
During IRI, TEC are invariably injured and potentially killed as a result of
increased stresses and host immune responses. This leads to DAMP release from
the TEC and the subsequent activation of immune cells effectors including
dendritic cells, T cells, B cells, macrophages and NK cells. Once activated, these
effectors cells contribute to further injury of TEC via the up-regulation of proinflammatory cytokines and chemokines as well as direct killing.
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1.4 Recurrent problems in chronic renal allograft survival
Apart from acute graft rejection, chronic allograft rejection (CAR) presents a persistent
and greater clinical obstacle, as it occurs in up to 60% of renal allografts. The onset of
CAR varies among patients, with injury being apparent as early as months or as late as
several years post-transplantation11. The most significant components of CAR are tubular
atrophy108, tubulointerstital inflammation109, and fibrosis110, which can also result from
recurrence of the original disease such as Focal Segmental Glomerulosclerosis
(FSGS)11,111. These result in a gradual but steady decline in the allograft function. Among
the several pathophysiological aspects of CAR, renal fibrosis is currently considered as
the most important and difficult issue. It has been speculated that TEC injury and death
during the acute phase IRI causes a phenomenon known as epithelial-to-mesenchymal
transition (EMT). Onset of EMT results in fibroblast expansion which outcompetes the
regeneration of dead TEC and parenchymal cells within the graft112. While EMT has been
linked to other chronic kidney diseases as well113,114, there have been reports that EMT
may not be a major factor in the renal fibrosis observed115. Key players involved in
fibrogenesis of renal allograft are transforming growth factor-β (TGF-β)116,117, connective
tissue growth factor (C-TGF)118, and PINCH-1119,120. TGF-β signaling during renal IRI
promotes fibrogenesis and also activates p38 mitogen-activated protein (MAP) kinase
activity, which, interestingly accelerates the cleavage of pro-caspase-9, which is central
to intrinsic apoptosis121. TGF-β signaling also results in downstream activation of C-TGF.
C-TGF has been implicated in the profibrotic EMT that characterizes TGF-β signaling122,
and is currently a leading target for antifibrotic drugs strategies123. PINCH-1 is an adaptor
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protein that binds and stimulates integrin-linked kinase (ILK), and this interaction is
essential for TGF-β–mediated fibrosis119.
Currently, there are no effective immunosuppressive therapeutic strategies that can
attenuate or ameliorate CAR. Although a few studies have suggested possible roles of
acute phase IRI in permitting allograft tolerance124-127, there is a lack of convincing
evidence to support this. Understanding the complex underlying mechanisms of CAR
remains imperative for establishing clinically effective strategies to improve long-term
graft survival.

1.5 Receptor interacting protein kinase 3 (RIPK3)-mediated
necroptosis and caspase-8 dependent extrinsic
apoptosis in renal IRI
Modalities and involvement of TEC death in renal IRI has been well documented, as
many distinctive, unique forms of cell death exist and contribute to the graft injury. TEC
can undergo various forms of cell death including but not limited to FAS-mediated
fratricide17,91, caspase-dependent extrinsic128 and intrinsic apoptosis129,130, necrosis131,132,
secondary necrosis133,134, necroptosis135,136, ferroptosis137, pyroptosis138,139, autophagy140142

, and mitotic catastrophe143. Recent studies have shown necroptosis, a regulated form

of necrosis, plays a major role in exacerbating renal IRI144. Morphological and
biochemical characteristics of necroptotic death are indistinguishable from that of
necrosis145,146, as both show ATP depletion-induced swelling of the mitochondria and
cytoplasm, plasma membrane rupture, and lysis of the cell147,148. For a long time, necrosis
has been understood as an unregulated and “messy” form of cell death131. This perception
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has been altered with the recent demonstration of regulated forms of necrosis including
necroptosis149,150. Necroptosis possesses characteristics of apoptosis in being
programmed and sharing some components with necrosis; it not only depends on
programmed and controlled endogenous cellular machinery as in apoptosis151, but also
leads to cell lysis and leakage of intracellular contents that act as immunogenic
DAMPs152. Necroptosis was in fact classified as a “failsafe” mechanism against
infections from caspase-8 inhibiting viruses153,154.
Interactions between various death receptors and ligands are capable of triggering
necroptosis, as activation of TNF receptor-1 (TNFR-1)155, FAS156, TNF-related apoptosis
inducing ligand (TRAIL)157,158, and TLR 4159 signaling can all result in necroptosis,
although the downstream pathways differ160,161. Most necroptotic pathways rely on the
activation of RIPK1 and RIPK3, two serine/threonine kinase family members whose
presence is essential for the formation of the necrosome complex162-164. Upon deathreceptor activation, multiple adaptor proteins165 including poly-ubiquitinated RIPK1166
are recruited to the cytosolic domain of the receptors, forming Complex I167. The
modification of the RIPK1 ubiquitin tail determines the fate of the cell at this point168. If
NF-κB essential modulator (NEMO) binds to the M1-linked chain of the ubiquitin tail,
the subsequent result is an increased stability of Complex I. Furthermore, NEMOubiquitin tail interaction causes activation of IκB kinase (IKK) by inducing its
conformational change and promoting NF-κB signal transduction cascade, which is proinflammatory and pro-survival.
On the other hand, the ubiquitin tail can be cleaved off by enzymatic molecules such as
A20169 or cylindromatosis (CYLD)170,171. With cleavage of the polyubiquitin tail,
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Complex I proceeds to formation of Complex II, with both RIPK1 and RIPK3 attached to
it145,172. As in Complex I, Complex II faces two potentially different outcomes. If
caspase-8 is recruited, it cleaves the kinase domains of both RIPK1173 and RIPK3174,
rendering the kinases nonfunctional and resulting in activation of downstream caspase-8
mediated apoptosis. This ends in prototypical, “clean,” non-inflammatory death of the
cell175. In the alternative situation where caspase-8 recruitment is absent, necroptosis
occurs. Without the inhibitory action of caspase-8, RIPK3 can phosphorylate RIPK1176,
which then autophosphorylates itself153. This results in necrosome formation, as RIPK1
and RIPK3 heterodimerize using their RIP homotypic interaction motif (RHIM)
domains153,162,163. Activated RIPK3 starts the activation of downstream molecules, and
mixed lineage kinase domain-like (MLKL) is a primary RIPK3 target. MLKL lacks an
active kinase domain177, and it is phosphorylated by RIPK3178. These phosphorylation
events are indispensable for necroptosis, as depletion of either RIPK3 or MLKL has
shown to shift cell death from necroptosis to RIPK1-mediated apoptosis179.
Phosphorylated MLKL creates pore structures in the cell membrane to release DAMP. It
also proceeds to the outer mitochondrial membrane and activates downstream
mitochondrial phosphatase PGAM5180. Currently, the downstream kinetics of PGAM5 is
poorly understood, as there have been conflicting results as to the involvement of
mitochondrial molecules before necroptosis occurs181,182.
Necroptosis is an energy-dependent process, as highlighted by ATP depletion, ROS
production, and subsequent mitochondrial swelling which all can be attributed to
metabolic changes. Necroptosis however can proceed in the absence of mitochondria, so
the total amount of ATP needed to proceed must be quite limited183. Active RIPK3 also
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acts as a metabolism regulator by increasing the activity of multiple enzymes164.
Glutamine synthase (GLUL), glutamate dehydrogenase (GLUD1), and glycogen
phosphorylase (PYGL) are three metabolic enzymes that significantly contribute to
accumulation of ROS in the mitochondria during necroptosis184,185. These enzymes
participate in catabolism of glutamine, glutamate, and glycogen, thus accelerating and
intensifying the energy production within cells145. Metabolic stress up-regulates the
expenditure of endogenous ATP, ROS production, mitochondrial swelling, and lysis of
the cell, fulfilling the characteristics of necroptosis163,186. With the resulting release of
intracellular immunogenic DAMPs, and in the case of sepsis-PAMPs, necroptosis poses a
significant threat to TEC function and thus kidney transplant organ function.
Apoptosis is an innate mechanism required for cellular remodeling and repair, and is
considered as a prototypical ‘programmed’ cell death. Apoptosis is a predominant and
particularly intense form of death in kidneys, as TEC undergo rapid and frequent
turnover187. During renal IRI when apoptosis of TEC exceeds kidney’s regenerative
capacity, it can leads to loss of function and graft failure. Caspase-8 is a cysteine-aspartic
acid protease responsible for death receptor-mediated ‘extrinsic’ apoptosis, and its
activation during IRI is triggered by cytokines such as TNFα and FASL188,189, as well as
by gasotransmitters such as nitric oxide190. Caspase-8 promotes graft damage during IRI
through TEC apoptosis, and its inhibition thus would be expected to confer survival
benefits66,191. Initial stages of extrinsic apoptosis cascade share identical features with
necroptosis, such as assembly of Complex I, cleavage of polyubiquitin tail on RIPK1, and
Complex II formation post-death receptor activation. Caspase-8 recruitment to Complex
II results in cleavage of RIPK1 and RIPK3, inactivating necroptosis and diverting the fate
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of TEC towards apoptosis192. Activated caspase-8 further proceeds to cleave downstream
effector caspases-3, 6, and 7, all of which are also members of cysteine-aspartic acid
protease family, into their activated forms193-195. The activated executioner caspases
begins the demise of TEC, leading to DNA fragmentation, chromatin condensation, and
membrane blebbing.
The dual-function of caspase-8 in promoting apoptosis and also inhibiting necroptosis has
been clearly highlighted by embryonic lethality of caspase-8-/- mice, which occurs
around day 10. It has been demonstrated that RIPK3-mediated necroptosis was the cause
of the embryonic lethality in the absence of caspase-8 and loss of suppression of
necroptosis. The lethality of the caspase-8 loss can be recovered by the concurrent
removal of suppressed necroptosis196. These have been extremely important mouse
models to study the effect of cell death on organ function. This also highlights important
counter-balanced regulatory mechanisms that exist between apoptosis and necroptosis, as
well as the role of caspase-8 to act as a master “switch” in skewing cell death to apoptosis
or necroptosis. While there have been many genetic knockout models created to study the
mechanisms of death pathways and interactions of proteins involved in them197, it is
noteworthy that many of these pathways can be studied and inhibited by murine
cytomegalovirus (MCMV), which encodes inhibitors of cell death pathways and can
simultaneously inhibit many pathways198-200.
Strong evidence shows necroptosis and extrinsic apoptosis contribute to damage in renal
IRI. Until recently, reagents suitable for clinical study have only been directed against
apoptosis using caspase inhibitors. Recently, necrostatin-1 (Nec-1) has become the
leading candidate for clinical trials in suppressing necroptosis. It prevents necroptosis
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through allosteric inhibition of RIPK1 and has been shown to grant significant
cytoprotective and survival benefits201-203. Further studies are required in order to develop
effective therapeutic and pharmacological strategies. Targeting important cell death
mediators such as RIPK3 and apoptosis in combination should be considered, as it could
lead to attenuation of renal IRI and survival of renal allografts. However, as these are
counter balanced pathways with complex interactions, a detailed understanding of
mechanisms is required to avoid potentiation of other forms of cell death as well as
potential side-effects, as evidenced by the studies in this thesis.
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Figure 4. Mechanism of TNFα-induced necroptosis and apoptosis
After TNFα-TNFR-1 interaction, assembly of Complex I consisting of TRADD,
ubiquitinated RIPK1, CIAPs, and TRAF2/5 occurs at the cytosolic tail domain of
TNFR-1. NEMO binding to the ubiquitin tail of RIPK1 activates the pro-survival/proinflammatory NF-κB signaling pathway, whereas removal of the ubiquitin tail by A20
or CYLD allows Complex I to proceed and form DISC/Complex II. If pro-caspase 8
is recruited by FADD and activated into active caspase-8, it will prevent necroptosis
by cleaving RIPK1 and RIPK3, and initiate apoptosis through caspase-3, 6, and 7
activation. Caspase-8 mediated apoptosis can be inhibited by endogenous cFLIP-L,
vCIA of MCMV, or pan-caspase inhibitor Z-vad-fmk to allow RIPK1-RIPK3
necrosome complex (Complex IIb) formation. Active necrosome complex further
activates downstream MLKL and PGAM5 to initiate necroptosis. Necroptosis can be
prevented by RIPK1 inhibition through Nec-1 or RIPK3 inhibition by vIRA of
MCMV.
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1.6 B-cell lymphoma-2 (BCL-2) family members and
intrinsic apoptosis in renal IRI
Along with extrinsic apoptosis and necroptosis, intrinsic apoptosis is another form of
death that cells can undergo during renal IRI. These three pathways could all relate to
mitochondria in their downstream executioner mechanisms, as they may interact with
each other at the mitochondrial level during renal IRI204,205.
In order to maintain mitochondrial homeostasis, complex interactions amongst B-cell
lymphoma 2 (BCL-2) protein family members are required206. BCL-2 family proteins
have long been known as key players in mediating cell survival and death through
mitochondria207 and can be classified into two subgroups of pro-apoptotic or antiapoptotic proteins208. Pro-apoptotic members such as BCL-2 associated X protein (BAX),
BCL-2 homologous antagonist killer (BAK), and BCL-2 associated death promoter
(BAD), BH3 interacting-domain death agonist (BID), and BCL-2-interaction mediator of
cell death (BIM) causes a cascade of interactions that results in mitochondrial/intrinsic
apoptosis under stress stimuli209. Anti-apoptotic members BCL-2, B-cell lymphoma-extra
large (BCL-xL), and induced myeloid leukemia cell differentiation protein (MCL-1) act
as inhibitors of the intrinsic apoptosis by physically binding to their pro-apoptotic
counterparts and inhibiting their functions through degradation and sequestration210.
During renal IRI, TEC experience a variety of physiological stress, including acidic pH142
and ROS production211. Under stress, TEC begin to up-regulate mRNA expressions of the
BCL-2 family212, with the largest difference seen in BAX levels which remain elevated
up to 7 days post-surgery213. Cytosolic BAX is activated and translocates to organelle
membranes214 primarily onto mitochondrial outer membrane (MOM)215, where it
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undergoes conformational change216,217. BAX facilitates the opening of voltagedependent anion channel-1 (VDAC-1) by directly binding to VDAC-1 and forming a
BAX-VDAC-1 heterodimer218. Transiently, VDAC-1 opening induces downstream
mitochondrial permeability transition pore (MPTP) formation and mitochondrial inner
membrane (MIM) permeability219. Along with cyclophilin D in the intermembrane matrix
and adenine nucleotide translocatior (ANT) on the inner mitochondrial membrane,
VDAC forms the MPTP complex220,221, and promotes the loss of mitochondrial
membrane potential (MMP) and swelling, MIM permeability, and secondary rupture of
of the MOM222. This secondary rupture represents a ‘point of no return’ as massive
release of cytochrome c from the intermembrane space follows223 and results in
apoptosis224. However, recent studies have suggested that BAX may facilitate intrinsic
apoptosis by forming mitochondrial apoptosis-induced channel (MAC) through which
cytochrome c is released225. This MAC formation theory follows the same concept in
BAX translocation onto MOM, but suggests that BAX opens up MAC via
homodimerization and heterodimerization with BAK which is constitutively bound to
MOM214,226. Released cytochrome c binds to apoptotic protease activating factor 1
(APAF-1) and forms a holoenzymatic apoptosome complex in a dATP-dependent
manner227. Apoptosome formation is accompanied by synchronized pro-caspase-9
recruitment to Caspase Activation and Recruitment Domain (CARD) present on the Nterminus of APAF-1228. The precise mechanism of caspase-9 activation remains
unknown, as two conflicting theories exist. While apoptosome may directly mediate
cleavage and activation of pro-caspase-9229, recent studies suggest that apoptosome
indirectly induces caspase-9 activation by aiding pro-caspase-9 dimerization and
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autocatalysis230,231. Active caspase-9 proceeds to cleave the downstream executioner procaspases-3, -6, and -7, and completing the cytochrome c-mediated feedback loop232,233.
Active executioner caspases cleave Inhibitor of Caspase Activated DNase (ICAD),
allowing localization of caspase activated DNase (CAD) into the nucleus and triggers the
subsequent fragmentation of DNA, as well as degradation of numerous intracellular
proteins195. As noted previously, up-regulation of TGF-β in TEC during renal IRI further
augments intrinsic apoptosis212,234 by potentiating pro-caspase-9 cleavage121, thus
highlighting the importance of intrinsic apoptosis in graft injury.
However, the intrinsic apoptosis cascade is strictly regulated both upstream and
downstream of mitochondria by anti-apoptotic BCL-2, BCL-xL, and MCL-1
proteins208,209. There seems to be a benefit conferred by anti-apoptotic proteins as over
expression and augmentation of BCL-xL results in the reduction of IRI-induced TEC
apoptosis and autophagy235. BCL-2 and BCL-xL form heterodimers with cytosolic BAX
to prevent its translocation to MOM236. In its dephosphorylated state, BAD
heterodimerizes with BCL-2 and BCL-xL, rendering them inactive and allowing BAX
translocation to MOM. Protein kinase B (PKB) and insulin-like growth factor-1 (IGF-1)
are two examples of proteins that mediate BAD phosphorylation and consequent
formation of 14-3-3- BAD heterodimers causing dissociation of BAD from BCL-2 and
BCL-xL237-239. During apoptosis, BAD dephosphorylation is mediated by calcineurin240,
protein phosphatase 1 (PP1α)241, and 2A (PP2A)242. This leads to BAD
heterodimerization with BCL-2, BCL-xL, or MCL-1, allowing dissociation of BAX and
BAK and downstream apoptosis cascade243. BCL-xL is also capable of stopping the
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intrinsic apoptosis after release of cytochrome c, as BCL-xL binds to APAF-1 and
prevent pro-caspase-9 cleavage244.
Intrinsic apoptosis of TEC has been extensively studied, and considerable evidence
supports its involvement in both renal IRI and allograft rejection239. BCL-2 expression
greatly decreases in TEC during renal IRI245, and chemotherapeutic agents such as
cisplatin have been shown to cause severe nephrotoxicity via DNA damage, which leads
to p53-mediated Apoptosis Inducing Factor (AIF) activation and apoptosis of TEC246,247.
However, discoveries of alternatively spliced isoforms of BCL-2 family members whose
roles are yet unclear suggest there are as yet unknown interactions and kinetics of
intrinsic apoptosis mediators248. One example is the recent discovery of caspase-3’s
ability to cleave BCL-2 and converting it to pro-apoptotic BAX-like death effector
protein249. The lack of understanding is reflected by four different proposed models of
BCL-2 family interaction250. Since TEC can undergo cell death by intrinsic apoptosis in
the absence of RIPK3 and caspase-8, due to intact mitochondria, it remains that better
understanding of the dynamics of IRI-induced intrinsic apoptosis would benefit devising
strategies to reduce IRI and prolong graft survival.

28

Stress$S-muli$

vIBO$

BAK$

BAX$

MAC$
Forma-on$
BAX$

BIP,$
vMIA$

VDAC1$

BCL7XL$

BAX$

MPTP$
Forma-on$$

Cytochrome$C$
release$

BCL72$

BAD$

Apaf71$

BCL7XL$
BAD$

BAD$
BCL72$

Pro7caspase79$

DNA$
Fragmenta-on$

Pro7caspase79$

CAD$

Apoptosome!Heptamer$

Caspase79$

Caspase73$

Pro7caspase73$

CAD$
ICAD$

Figure 5. Mechanism of stress-induced intrinsic apoptosis
Stress stimuli including hypoxia and cytokines during IRI induce BAD
dephosphorylation. BAD binds to anti-apoptotic BCL-2 and BCL-XL and inhibits
their function, allowing dissociation of BAX. Free BAX translocates to mitochondria
and starts the cascade of downstream effector molecule activation leading to
mitochondrial depolarization, apoptosome formation, and caspase cleavage. Intrinsic
apoptosis can be inhibited through BAX inhibition by BIP or vMIA protein of
MCMV, or by BAK inhibition by vIBO protein of MCMV.
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1.7 Hypothesis
We hypothesize that intrinsic apoptosis contributes to renal IRI but due to the counterbalanced nature of programmed cell death, it may be dysregulated in cells unable to
undergo necroptosis or extrinsic apoptosis. Dysregulation or up-regulation of intrinsic
apoptosis may counteract the benefits conferred by inhibition or loss of RIPK3. As cells
lacking pathways of programmed cell death have intact NF-κB and other pathways, we
hypothesize that DKO TEC exposed to death ligand may demonstrate up-regulation of
pro-inflammatory cytokine and chemokine production post-activation.

1.8 Specific aims
1. To show presence of remaining forms of cell death in TEC in the absence of
necroptosis and caspase-8 dependent extrinsic apoptosis.
2. To investigate the effect of pro-inflammatory activation of TEC in the absence of
RIPK3 and caspase-8 programs of cell death.
3. To explore the possibility of alleviating renal IRI by simultaneously inhibiting multiple
cell death pathways including intrinsic apoptosis.

30

Chapter 2

2

Materials and Methods

2.1 Animals
C57BL/6 (H-2b) mice were purchased from commercial sources (Jackson Laboratories,
Bar Harbor, ME), the B6 RIPK3-/- (H-2b) were generously provided by Dr. Kim Newton
(Genentech)251, and the combined B6 RIPK3-/- Caspase-8-/- (H-2b) (DKO) were provided
by Dr. Douglas Green (St. Jude Children’s Research Hospital, TN)192. Mice were
maintained in the animal facility at the Western University and regularly screened for
pathogens. RIPK3-/- mice are phenotypically unremarkable, and have normal kidney
function and breeding251. RIPK3-/- Caspase-8-/- mice are normal phenotypically at a
young age, but develop lymphadenopathy by four months of age due to accumulation of
abnormal double negative T (DNT) cells in the periphery196. Animal experiments were
conducted in accordance with the Canadian Council on Animal Care guidelines under
protocols approved by Western University.

2.2 Antibodies
Cell surface death receptor expressions were quantified with staining with PE-conjugated
anti-TNFR-1 (eBiosciences), anti-DR5 (eBiosciences), anti-TLR 2 (eBiosciences), antiTLR 4 (eBiosciences), and FITC-conjugated anti-TNFR-2 (Abcam) and anti-FAS (BD
Pharmingen). All experiments were analyzed on a Cytomics FC500 flow cytometer
(Beckman Coulter, Mississauga, ON).
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2.3 Tubular epithelial cell (TEC) culture
Primary TEC cultures were obtained from the cortex region of kidneys from wild type,
RIPK3-/-, and RIPK3-/- Caspase-8-/- mice with a C57/BL6 background, by digestion with
collagenase V at 1 mg/mL (Sigma) for 15 min in complete K1 media in a humidified
incubator at 37 °C. The digested cells were then passed through a 40 µm cell strainer (BD
Biosciences, San Jose, CA) and washed with PBS solution. The primary TEC were
grown to a confluent monolayer inside 75 cm2 vented flasks (BD Biosciences)
supplemented with complete K1 culture medium (DMEM/Hams F12, 50:50; Invitrogen)
supplemented with 5% bovine calf serum, hormone mix (5g/ml insulin, 1.25ng/ml
prostaglandin E1, 34pg/ml triiodothyronine, 5g/ml transferrin, 1.73ng/ml sodium selenite,
and 18ng/ml hydrocortisone), and 25ng/ml epidermal growth factor in a humidified
incubator at 37 °C. The primary TEC were immortalized through lipofection of origindefective SV40 using Lipofectamine 2000 reagent (Invitrogen) to be used for in vitro
experiments. Phenotype of the TEC was confirmed using PE conjugated anti-CD 13
(Abcam), FITC conjugated anti-CD26 (BD Pharmingen), and FITC conjugated anti-Ecadherin (BioLegend)43. 0.05% Trypsin-EDTA was used to passage the cells.

2.4 Fibroblast culture and MCMV propagation
NIH 3T3 fibroblasts were grown in 4.5g/ml glucose DMEM (Invitrogen) mixed with
10% fetal bovine serum, 2 mM L-glutamine, 100U/ml penicillin, and 100U/ml
streptomycin (Invitrogen)252. Stocks of wild-type K181 BAC MCMV strain were
generously provided by Dr. Edward Mocarski (Emory University, GA)253. K181 BAC
strain was grown and propagated on NIH 3T3 cells254, and crude stocks for in vitro
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experiments were prepared as described255. TEC were infected with MCMV at MOI of 5
for 24 hours before treatment.

2.5 Kidney ischemia reperfusion injury (IRI)
A renal clamp was applied to the right kidney pedicle and removed after 45 minutes. The
mouse was kept at 34°C and the left kidney was removed19,43,256. Kidneys were collected
at 48h post- IRI after being flushed with normal saline. Serum creatinine levels were
tested by using an automated CX5 clinic analyzer (Beckman, Fullteron, CA).

2.6 RNA isolation and real-time polymerase chain reaction
(RT-PCR)
Total RNA extraction from cultured TEC were performed with Trizol (Invitrogen,
Carlsbad, CA). cDNA was generated using Superscript II (Invitrogen) and quantified by
real-time polymerase chain reaction (RT-PCR) MX3005 (Stratagene, Santa Clara, CA)
using SYBR QPCR Master Mix kit (Bio-Rad, Hercules, CA). β-actin amplification was
used as the endogenous control. RT-PCR was performed with standard amounts of cDNA
using the SYBR qPCR Master Mix kit (BioRad) and the normalized delta threshold cycle
(Ct) value and relative expression levels (ΔΔCt) were calculated according to the
manufacturer’s protocol. Primers used in the RT-PCR include: β-actin: 5’CTGTGCTATGTTGCTCTA-3’ and 5’-AGGATTCCATACCCAAGA-3’, BAX: 5’TTTGCTACAGGGTTTCAT-3’ and 5’-GTCCAGTTCATCTCCAAT-3’, BAK: 5’CATGAATCCACTGATACCA-3’ and 5’-GTCACTTGTCACCTGAAT-3’, BAD: 5’CGATGAGTTTGAGGGTTC-3’ and 5’-CTTTGTCGCATCTGTGTT-3’, BID: 5’-
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GGTTAGAAACGAGATGGA-3’ and 5’-	
  AACTCTTCAGATACACTCA-3’, BIM: 5’TGACAGAATAAGAGGACTT-3’ and 5’-CAGGCAGAACTAAGATTG-3’, BCL-2:
5’-ACTGAATGTAGATAATGG-3’ and 5’-TAACTGTAACTGATAAGG-3’, BCL-XL:
5’-ATAACCTTATCTTGGCTTTGG-3’ and 5’-AACACCTGCTCACTTACT-3’, MCL1: 5’-GATTGGCATTCTTGGATTG-3’ and 5’-GAACACAGTCATACTTGGA-3’,
MCP-1: 5’-AGCTGTAGTTTTTGTCA-3’ and 5’-GGTCAACTTCACATTCAA-3’,
RANTES: 5’-ATATGGCTCGGACACCACTC-3’ and 5’TCCTTCGAGTGACAAACACG-3’, and IL-6: 5’GAGGATACCACTCCCAACAGACC-3’ and 5’AAGTGCATCATCGTTGTTCATACA-3’.

2.7 Cell viability and death assays
TEC were grown to confluent monolayers and treated with cyclohexamide (CHX)
(Sigma), recombinant human TNFα (hTNFα) (Peprotech), and lipopolysaccharide (LPS)
(Sigma). Cell death was detected with propidium iodide (PI) or Annexin-V labeling (BD
Bioscience) and analyzed by flow cytometry (Beckman Coulter). TEC were also treated
with murine interferon-γ (IFN-γ; Peprotech, Rocky Hill, NJ), interleukin-1β (IL-1β; R&D
Systems, Minneapolis, MN), and Bax-inhibiting peptide V5 (BIP; Sigma, Oakville, ON,
Canada) in serum-free media. After 24 hours, TEC were incubated with 12mM MTT
(Life Technologies, Burlington, ON, Canada) for 4 hours before absorbance was
measured at 490nm. Untreated TEC were set as 100% viable. Cell death was quantified
using the Sytox Green reagent (Essen Bioscience, Ann Harbor, MI). 100nM of Sytox
Green reagent was added to wells containing TEC. Incucyte ZOOM (Essen Bioscience)
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live cell imaging incubator was used to scan for Sytox Green positivity at 30-45 min
intervals over 24 hours.

2.8 Caspase-9 and caspase-3 assays
To quantify caspase-9 activity, luciferase activity dependent on caspase-9–mediated
generation of luciferase substrate was measured. TEC were grown to confluent
monolayers and treated with IFN- γ, IL-1β, and BIP for 24 h. 70uL of Caspase-Glo-9
reagent (Caspase-Glo-9; Promega, Madison, WI) was added directly to the TEC cultures.
Luminescence emission was detected after 1 hour using a VictorX Light (PerkinElmer).
Cleaved caspase-3 activity was measured using CellPlayer™ Kinetic Caspase-3/7
Apoptosis Assay Reagent (Essen Bioscience, Ann Harbor, MI). 5 µM of the CellPlayer™
Kinetic Caspase-3/7 Apoptosis Assay Reagent was added to wells containing TEC and
Incucyte ZOOM (Essen Bioscience) live cell imaging incubator was used to scan for the
reagent positivity at 30-45 min intervals over 24 hours.

2.9 Histology and immunochemistry
Kidney sections were stored in 5% formalin (Sigma) for at least 3 days and fixed in
paraffin before being stained with hematoxylin and eosin (H&E). The slides were scored
for acute tubular necrosis by a pathologist in a blinded fashion (0: no change, 1: <25%
area change, 2: 25–50% area change, 3: 50–75% area change, 4: 75% area change) using
a semiquantitative method as described43,257,258.
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2.10 Statistical analysis
For parametric data, One way- and Two way- Analysis of Variance (ANOVA) tests were
used to compare multiple groups, and Student’s t-test was used for unpaired values.
GraphPad Prism software (GraphPad Software, Inc., La Jolla, CA) was used for all
statistical analysis. Data are presented as mean ± SEM using p<0.05 for significance
unless specified.
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Chapter 3

3

Results

3.1 Loss of RIPK3 and caspase-8 does not show additional
benefits over RIPK3 deletion alone in renal IRI
Blocking necroptosis with the RIPK1 inhibitor Nec-1 can significantly attenuate damage
due to renal IRI136. Similarly, RIPK3-/- mice are more resistant to kidney damage post
IRI135. Silencing of caspase-8 as well as FAS (CD95) by siRNA and has shown to be of
benefit in a mouse IRI model259. However, remaining residual injury in these models may
reflect that total injury was related to the sum of individual pathways of cell injury and
death. Recently DKO mice became available to study, as the loss of caspase-8 is
embryonic lethal and is salvaged by the genetic deletion of RIPK3. We thus decided to
investigate the potential benefit of inhibition of both RIPK3 and caspase-8 by subjecting
wild type, RIPK3-/-, and DKO mice to renal IRI as described19. Kidney and serum
creatinine samples were collected at 48h post-IRI to assess ATN and kidney function,
respectively. We confirmed that the absence of RIPK3 resulted in improved kidney
function as shown by lower serum creatinine levels post-IRI (51 ± 20 umol/L in IRItreated RIPK3-/- vs. 118 ± 24 umol/L in IRI-treated wild type C57BL/6 mice, n=9/group,
p=0.04, Figure 6A). In contrast, DKO mice did not show any further improvements
compared to RIPK3 knockout alone, and indeed DKO mice showed slightly increased
serum creatinine levels (82 ± 38 umol/L in IRI-treated DKO mice vs. 51 ± 20 umol/L in
IRI-treated RIPK3-/- mice, p>0.05, n=6-9/group). Histological assessment of ATN
showed similar results, where wild-type mice showed higher injury scores compared to
both RIPK3-/- (2.5 ± 0.1 vs. 1.5 ± 0.2, n=4/group, p=0.007, Figure 6B) and DKO mice
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(2.5 ± 0.1 vs. 1.6 ± 0.1, p=0.0014, n=4-8/group). Consistent with serum creatinine levels,
DKO mice showed no improvement over RIPK3-/- mice (Injury score 1.6 ± 0.1 vs. 1.5 ±
0.2, p=0.75, n=4-8/group). Therefore, in contrast to our original belief that combined loss
of both caspase-8 apoptosis and RIPK3 necroptosis would improve IRI by eliminating
independent pathways of injury within the kidney, our data clearly demonstrates that the
absence of both RIPK3 and caspase-8 does not result in any further benefit compared to
RIPK3 loss alone. As these pathways of cell death share components and are counterbalanced in some cases, such as caspase-8 control of necroptosis, these data suggest that
there may be an interaction on remaining forms of cell death or a compensating
mechanism that attenuated the expected benefit.
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Figure 6. Loss of RIPK3 and caspase-8 does not show additional benefits over RIPK3
deletion alone in renal IRI
A renal clamp was applied to the right kidney pedicle of wild type C57BL/6, RIPK3-/-, and
RIPK3-/- Caspase-8-/- (H-2b), and was removed after 45 minutes at 34°C and the left kidney
was collected. Kidneys and serum creatinine were collected at 48h post- IRI to measure
acute tubular necrosis and kidney function, respectively. A. Serum creatinine levels were
tested by using an automated CX5 clinic analyzer (n=6-9/group, *: p <0.05, Two-Way
ANOVA). B-C. Obtained kidneys were fixed in formalin at the time of sacrifice and stained
with H&E. Slides were scored for acute tubular necrosis by a pathologist in a blinded
fashion (0: no change, 1: <25% area change, 2: 25–50% area change, 3: 50–75% area
change, 4: 75% area change) using a semiquantitative method. (n=4-8/group, **: p <0.01,
One-Way-Anova)
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3.2 Establishment and characterization of the C57BL/6
tubular epithelial cell line
Immortalized wild type B6, RIPK3-/-, and DKO TEC cell lines were generated from
C57BL/6 kidneys as described in the methods for in vitro experiments. The cobblestone
phenotype of TEC was confirmed by morphology (Figure 7A), and CD13, CD26, and Ecadherin positivity were analyzed by flow cytometry (Figure 7B).
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Figure 7. Establishment and characterization of the C57BL/6 tubular epithelial cell
line
TEC were isolated and immortalized with origin deficient SV40 DNA. A. Cells were
grown as monolayers and the typical cobblestone phenotype of epithelial cells was
confirmed using Incucyte Zoom live cell tracker at 20 X magnification. B. Cells were also
analyzed for the presence of the epithelial markers CD13, CD26 and E-cadherin by flow
cytometry.
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3.3 Death receptor expressions in the TEC do not change
with cytokine stimulation
The absence of caspase-8 or RIPK3 may have altered the expression of surface receptors,
as for example; the loss of FAS increases the expression of FASL in other cells. We
therefore investigated for expression level differences of various cell surface death
receptors across the three cell lines, as a potential compensation for the loss of RIPK3
and caspase-8. As well during IRI, regulation of numerous genes that contribute to IRI
are affected234, which includes the up-regulation of cell surface death receptors that
contributes heavily in promoting inflammation and death of TEC260. The current
knowledge of whether there are any regulational differences of the surface death
receptors in the absence of RIPK3 and caspase-8 is limited. The expression levels of
TNFR-1, TNFR-2, FAS, DR 5, TLR 2, and TLR 4 in the three cell lines were surveyed
using FACS analysis, as all have been associated with IRI-induced damage. As shown in
Figure 8, the basal expression levels of these death receptors on TEC was not found to be
different across the cell lines. As well, treating the cells with the combination of 10ng/mL
TNFα and 250U/mL IFNγ to activate the TEC did not up-regulate these receptors.
Therefore, the absence of RIPK3 and caspase-8 does not change cell surface death
receptor expression to account for any increased injury or death in DKO mice, or to
account for absence of benefit with IRI. Similar results were obtained with primary TEC.
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Figure 8. Death receptor expressions across the cell lines do not change with
cytokine-mediated activation
TEC were cultured as described in the methods. TEC were treated with 10ng/mL TNFα
and 250U/mL IFN-γ for 24 hours in serum-free media. TEC were analyzed for surface
expression levels of TNFR-1, TNF-R2, FAS, DR5, TLR 2, and TLR 4 by flow
cytometry. Figure values represent the mean ± SEM of three independent experiments
(n=3, Two-Way-ANOVA).
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3.4 TEC have endogenous resistance to cell death
After observing no differences in cell surface death receptor expression, we next
attempted to induce cell death in TEC in vitro and assess for potential differences in cell
death using the combination of CHX + TNFα and LPS, as they are classic activators of
receptor-mediated death pathways. In previous work, we have used additional exposure
to IFNγ to promote cell death. TEC were treated with combination of 1 ug/mL of CHX,
300 ng/mL of hTNFα, and 1 ug/mL LPS for 24 hours and cell death was determined by
Annexin-V and PI staining using flow cytometry. Since murine TNFα signals through
both TNFR-1 and TNFR-2 and promotes both cell death and survival pathways
respectively261,262, hTNFα was used to maximize TNFR-1-mediated cell death due to its
preferential binding and activation of TNFR1-mediated death pathways263. The addition
of CHX further enhances this process136,264. LPS binds and activates TLR 2265,266, as well
as TLR 4267,268. TLR activation leads to recruitment of adaptor protein TIR-domaincontaining adaptor-inducing interferon-β (TRIF)269,270, which interacts with RIPK1 and
RIPK3 complexes using RHIM domain and thus activates necroptosis271. As shown in
Figure 9, CHX + hTNFα increased Annexin-V in the wild type cells corresponding to
increased apoptosis. LPS treatment had no additional effect. These treatments had no
effect on either the RIPK3-/- TEC or the DKO TEC and death in the TEC after 24 hours
was similar to untreated controls. We observed similar results with primary TEC. This
demonstrates that TEC are generally resistant to receptor-induced death but, importantly,
there were no differences between DKO and other TEC to account for our in vivo results
in IRI.
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Figure 9. DKO TEC are not more sensitive to death induced by death receptors
than RIPK3-/- or wild type TEC
Wild type, RIPK3-/-, and DKO TEC were each plated in equal numbers (2.5 x 10^5)
and treated with CHX (1 ug/mL) + hTNFα (300 ng/mL) and LPS (1 ug/mL) for 24
hours in serum-free media. Cell death was characterized with Annexin-V and PI
staining using flow cytometry analysis. Figures here are representative of five
independent experiments in which the pattern of response was similar.

50

3.5 Absence of RIPK3 and caspase-8 sensitizes TEC to
death induced by the combination of IL-1β and IFN-γ
Alternate forms of cell death can be enhanced with perturbations of regulated cell death
pathways, and TEC are clearly capable of undergoing other forms of cell death
independent of RIPK3 and caspase-8. Since no additional benefits in renal IRI were
observed from in vivo IRI experiments (Figure 6), we hypothesized that loss of both
RIPK3 and caspase-8 might be sensitizing TEC to another form of cell death. Caspase-9
dependent intrinsic pathways of apoptosis should be intact in TEC even with loss of
caspase-8 or RIPK3, but has not been tested before. Since IL-1β and IFN-γ combination
is known to induce BAX-dependent intrinsic apoptosis in other cell types272, we
performed repeated concentration finding assays by treating TEC with various amounts
of IL-1β and IFN-γ in combination. We determined that 4 ng/ml of IL-1β and 120 ng/mL
of IFN-γ most effectively induced TEC death (viability 68.7 ± 0.9 % in IL-1β + IFN-γ
treated wild type vs. 100 % in untreated wild type, n=4, p<0.0001; 79.2 ± 2.8 % in IL-1β
+ IFN-γ treated RIPK3-/- vs. 100% in untreated RIPK3-/-, n=4, p=0.0018; 32.5 ± 10.1 %
in IL-1β + IFN-γ treated DKO vs. 100 % in untreated DKO, n=4, p=0.0026, Figure 10).
Interestingly, DKO TEC treated with IL-1β + IFN-γ showed greatest decrease in survival
compared to wild type (viability 32.5 ± 10.1 % vs. 68.7 ± 0.1 %, n=4, p=0.024) and
RIPK-/- TEC (viability 32.5 ± 10.1 % vs. 79.2 ± 2.8 %, n=4, p=0.011). Since MTT assays
were used which measures total survival, it was not possible from these experiments to
confirm the type of cell death induced by the IL-1β + IFN-γ combination that accounted
for the decreased cell viability we observed in DKO TEC. However, our results show that
in the absence of necroptosis and extrinsic apoptosis, TEC appear to have an increased
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sensitivity to IL-1β + IFN-γ induced death. As this induces intrinsic apoptosis in other
cells, it follows that DKO TEC may be more sensitive to induction of intrinsic apoptosis.
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Figure 10. Absence of RIPK3 and caspase-8 sensitizes TEC to death induced by the
combination of IL-1β and IFN-γ
Wild type, RIPK3-/-, and DKO TEC were cultured as described and treated with
combination of 4 ng/mL of IL-1β and 120 ng/mL of IFN-γ for 24 hours. Cell viability was
measured and quantified using MTT assay analyses. This figure represents one of four
independent experiments that showed the same responses (n=4, *: p < 0.05, **: p<0.01,
****: p<0.0001, Two-Way ANOVA).
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3.6 Absence of RIPK3 and caspase-8 result in basal level
mRNA up-regulation of pro-apoptotic BAX and BAK
BCL-2 family proteins are key mitochondrial mediators and regulators of apoptosis250,
and their roles in regulating TEC death in IRI have been well documented212,213. Studies
have shown that apoptotic stimuli such as IL-1β + IFN-γ mediate the activation of proapoptotic BAX, BAK, and BAD243,273,274. Upon our observation that DKO TEC are
significantly more sensitized to IL-1β + IFN-γ induced death (Figure 10), we
hypothesized that this may involve transcriptional level differences of mitochondrial
factors. We therefore assessed basal mRNA levels of BCL-2 family members in each of
the cell lines using RT-PCR. We noted that basal levels of BAX, BAK, and BAD in
DKO TEC were higher than wild type or RIPK3-/- TEC. As shown in Figure 11Ai-ii,
compared to RIPK3-/- TEC, DKO TEC showed significant basal level up-regulation of
pro-apoptotic BAX (1.7 ± 0.2 vs. 0.8± 0.1, fold of change, n=3/group, p=0.036, Figure
11Ai) and BAK (9.4 ± 0.3 vs. 2.4 ± 0.3, fold of change, n=3/group, p<0.0001, Figure
11Aii). Level of BAD was higher in DKO TEC compared to RIPK3-/- TEC (7.4 ± 2.0 vs.
4.9 ± 1.1, fold of change, n=3/group, p=0.33) but was significantly higher than wild type
TEC (9.4 ± 0.3 vs. 1 ± 0, fold of change, n=3/group, p=0.035, Figure 11Aiii). Level of
BID was decreased in RIPK3-/- TEC compared to wild type TEC (0.61 ± 0.1 vs. 1 ± 0,
fold of change, n=3/group, p=0.015, Figure 11iv), and BIM showed no difference across
the cell lines (Figure 11v).
There was no significant difference of BCL-2 expression in DKO TEC compared to wild
type (155.1 ± 76.75 vs. 1 ± 0, fold of change, n=3/group, p=0.115) and RIPK3-/- TEC
(155.1 ± 76.75 vs. 1.3 ± 0.2, fold of change, n=3/group, p=0.116, Figure 11Bi).
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RIPK3-/- TEC showed reduction in BCL-xL compared to wild type TEC (0.5 ± 0.1 vs. 1 ±
0, fold of change, n=3/group, p=0.007, Figure 11Bii) but showed no difference compared
to DKO TEC. Level of MCL-1 was higher in DKO TEC compared to RIPK3-/- TEC (2.9
± 0.2 vs. 2.2 ± 0.4, fold of change, n=3/group, p=0.03) but significantly higher than wild
type TEC (2.9 ± 0.2 vs. 1 ± 0, fold of change, n=3/group, p=0.0003, Figure 11Biii).
These results suggest that in absence of RIPK3 and caspase-8, transcription of certain
pro- and anti-apoptotic members of BCL-2 family is altered, for reasons that are not
clear. Higher levels of pro-apoptotic BAX, BAK, and BAD, as well as anti-apoptotic
MCL-1 and BCL-2 were observed in DKO TEC. Our results show that the sensitization
to intrinsic apoptosis displayed by DKO TEC is due to predisposition from transcriptional
level up-regulation of pro-apoptotic BAX, BAK, and BAD. Even in normal growth
media, it is possible that signaling from surface receptors may alter mitochondrial
proteins in the absence of cell death by caspase-8 mediated apoptosis or by RIPK3mediated necroptosis.
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Figure 11. Absence of RIPK3 and caspase-8 affects basal level mRNA regulation of
BCL-2 family members in TEC
TEC were cultured as described in the methods. mRNA levels of Ai-v. pro-apoptotic BAX,
BAK, BAD, BID, BIM and Bi-iii. anti-apoptotic BCL-2, BCL-xL, and MCL-1 were
measured by RT-PCR as described in the methods. β-actin was used as loading control.
Figure represents one of three independent experiments that show the same result (n=3, *: p
< 0.05, **: p<0.01, ****: p<0.0001, One-Way ANOVA). Similar results were observed in
primary TEC.
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3.7 Loss of RIPK3 and caspase-8 augments BAX-mediated
intrinsic apoptosis in TEC
After observing the up-regulation of basal levels of BAX, BAK, and BAD in DKO TEC
and increased sensitivity to IL-1β + IFN-γ induced death, we next hypothesized that
death by intrinsic apoptosis in DKO TEC was dependent on BAX, as been shown in other
cell types. To confirm this, we exposed TEC to IL-1β + IFN-γ with or without BIP to
inhibit BAX. Consistent with our previous data (Figure 10), TEC treated with IL-1β +
IFN-γ showed decreased viability (survival 51.7 ± 2.1 % in treated wild type vs. 100 in
untreated wild type, n=3, p<0.001; 39.7 ± 5.5 % in treated RIPK3-/- vs. 100 in untreated
RIPK3-/-, n=3, p=0.0004; 17.9 ± 1.8 % in treated DKO vs. 100 in untreated DKO, n=3,
p<0.001, Figure 12Ai). The IL-1β + IFN-γ treatment was thus most effective in killing
DKO TEC compared to wild type or RIPK3-/- TEC. Survival of TEC using the BAX
inhibitor BIP (50uM BIP) was not different between the cell lines (survival 32.4 ± 5.1 in
wild type vs. 25.2 ± 3.2 in RIPK3-/-, n=3, p=0.29; 32.4 ± 5.1 in wild type vs. 28.3 ± 4.3 in
DKO, n=3, p=0.57; 25.2 ± 3.2 in RIPK3-/- vs. 28.3 ± 4.3 in DKO, n=3, p=0.58, Figure
12Aii). However, DKO TEC showed the greatest improvement in relative survival with
BIP treatment compared to wild type (relative improved survival %: 156 ± 7.9 vs. 62.1 ±
7.9, n=3, p=0.0011) and RIPK3-/- TEC (156 ± 7.9 vs. 69.0 ± 7.4, n=3, p=0.0013, Figure
12Aiii). Therefore, although there was more death in the DKO TEC, the addition of BAX
inhibition restored the survival of DKO TEC much more than in wild type or RIPK3-/TEC, supporting the previous data of enhanced intrinsic apoptosis in DKO TEC.
We also used Sytox Green reagent in conjunction with an Incucyte ZOOM live cell
imaging system as described to label and observe late apoptotic and early secondary
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necrotic TEC in real time over a span of 24 hours. Sytox uptake is increased in cells that
are undergoing cell death including necrosis and late apoptosis/early necrosis. IL-1β +
IFN-γ treatment induced cell death in all three cell lines (Sytox uptake 22940 ± 1998 in
treated wild type vs. 6881 ± 457.5 in untreated wild type, n=3, p<0.001; 23740 ± 3269 in
treated RIPK3-/- vs. 4323 ± 419.9 in untreated RIPK3-/-, n=3, p=0.0042; 33790 ± 2334 in
treated DKO vs. 901 ± 341.1 in untreated DKO, n=3, p<0.002, Figure 12Bi-iv). The
highest Sytox uptake after IL-1β + IFN-γ treatment was consistently observed in DKO
TEC. Furthermore, the addition of BIP decreased Sytox uptake in all cell lines, although
this achieved statistical significance in DKO TEC (6398 ± 2022 vs. 33790 ± 2334, n=3,
p=0.009) but not in wild type (17780 ± 523 vs. 22940 ± 1998, n=3, p=0.067) or RIPK3-/TEC (13400 ± 4007 vs. 23740 ± 3269, n=3, p=0.12, Figure 12Bi).
Since BAX-mediated intrinsic apoptosis relies on apoptosome-mediated caspase-9
activation228, which leads to downstream executioner caspase-3 activation193, we tested
caspase-9 and caspase-3 activity in TEC to more definitively determine whether cell
death was indeed intrinsic apoptosis. Caspase-9 activity was measured by luciferase
assays as described. TEC were treated with IL-1β + IFN-γ in the absence or presence of
50uM BIP for 24 hours to induce intrinsic apoptosis. Caspase-9 activity was measured
24 hours after treatment and was quantified by luminescence intensity. TEC treated with
IL-1β + IFN-γ showed up-regulation of caspase-9 activity (luminescence intensity 13730
± 601.2 in treated wild type vs. 6261 ± 467.3 in untreated wild type, n=3, p=0.0006;
10670 ± 1881 in treated RIPK3-/- vs. 3734 ± 292.4 in untreated RIPK3-/-, n=3, p=0.022;
19370 ± 2397 in treated DKO vs. 4119 ± 1236 in untreated DKO, n=3, p=0.0048, Figure
12C). Caspase-9 activity of IL-1β + IFN-γ treated TEC was thus higher in DKO than
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RIPK3-/- TEC (19370 ± 2397 vs. 10670 ± 1881, n=3, p=0.046), although statistical
significance was not achieved when compared to wild type TEC (19370 ± 2397 vs.
13730 ± 601.2, n=3, p=0.085). Interestingly, addition of BIP led to decreased caspase-9
activity only in DKO TEC (11070 ± 1342 vs. 19370 ± 2397, n=3, p=0.039) but not in
wild type (13710 ± 2308 vs. 13730 ± 601.2, n=3, p=0.99) or RIPK3-/- TEC (11650 ±
2285 vs. 10670 ± 1881, n=3, p=0.76).
To confirm whether up-regulation of caspase-9 activity resulted in the expected upregulation of downstream caspase-3 activity, we measured caspase-3 activity as
described. 5 µM of the CellPlayer™ Kinetic Caspase-3/7 Apoptosis Assay Reagent was
added to treated and untreated TEC. Incucyte ZOOM live cell imaging analyses were
used to scan at 30 minute intervals over 24 hours. The pan-caspase inhibitor Z-vad-fmk
was added to confirm caspase mediated apoptotic cell death. IL-1β + IFN-γ treatment
induced caspase-3 activity in all three cell lines (caspase-3 positivity 7636 ± 806.1 in
treated wild type vs. 4503 ± 120 in untreated wild type, n=3, p=0.018; 6605 ± 631.4 in
treated RIPK3-/- vs. 3207 ± 933.7 in untreated RIPK3-/-, n=3, p=0.039; 62760 ± 3808 in
treated DKO vs. 4310 ± 400.7 in untreated DKO, n=3, p<0.001, Figure 12Di-iv).
Consistent with our caspase-9 results, DKO TEC showed the greatest increase in caspase3 activity post-treatment compared to wild type (62760 ± 3808 vs. 7636 ± 806.1, n=3,
p=0.001) or RIPK3-/- TEC (62760 ± 3808 vs. 6605 ± 631.4, n=3, p=0.001 Figure 12Di).
The addition of BIP led to results similar to those observed in caspase-9 assays. Caspase3 activity decreased in DKO TEC (8199 ± 1078 vs. 62760 ± 3808, n=3, p=0.0002) but
not in wild type (8075 ± 1465 vs. 7636 ± 806.1, n=3, p=0.8) or RIPK3-/- TEC (8573 ±
1887 vs. 6605 ± 631.4, n=3, p=0.37). Z-vad-fmk was effective in all of wild type (285.7
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± 140 vs. 7636 ± 806.1, n=3, p=0.0008), RIPK3-/- (-521 ± 389 vs. 6605 ± 631.4, n=3,
p=0.0007), and DKO TEC (511.3 ± 49.74 vs. 62760 ± 3808, n=3, p<0.0001), and
addition achieved near-complete reduction of caspase-3 activity. Our data indicates the
loss of both RIPK3-mediated necroptosis and caspase-8-mediated extrinsic apoptosis
results in augmentation of caspase-9 and caspase-3 activities in TEC, which can be
recovered by addition of BIP and Z-vad-fmk. These results support that enhanced
intrinsic apoptosis occurs in DKO TEC.
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Figure 12. Loss of RIPK3 and caspase-8 augments BAX-mediated intrinsic
apoptosis in TEC
Immortalized wild type, RIPK3-/-, and DKO TEC were cultured as described and
treated with combination of 4 ng/mL of IL-1β and 120 ng/mL of IFN- γ with or
without 1 hour pre-incubation of 50uM BIP, or 50uM Z-vad-fmk for 24 hours. Ai-iii.
Cell viability was measured and quantified using MTT assay analysis, and Bi-iv. Sytox
Green was used to stain and quantify late apoptotic and early secondary necrotic cells.
C. Luminescence assay was used to measure caspase-9 activity and Di-iv. CellPlayer™
Kinetic Caspase-3/7 Apoptosis Assay Reagent was used to measure caspase-3 activity.
Figures represent one of three independent experiments, which showed the same
results (n=3, *: p < 0.05, **: p<0.01, ***: p<0.001, ****: p<0.0001, Two-Way
ANOVA).
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3.8 MCMV completely abrogates intrinsic apoptosis in TEC
In order to inhibit host cell death, certain viruses encode proteins that inhibit programmed
cell death to ensure their survival. One such virus, murine cytomegalovirus (MCMV),
possesses a potent and somewhat unique capacity to inhibit multiple cell death pathways
simultaneously with inhibitor proteins. Most notably, MCMV uses vCIA to inhibit
caspase-8 mediated extrinsic apoptosis275, vMIA and vIBO to inhibit BAX and BAKmediated intrinsic apoptosis198,200, and vIRA to inhibit RIPK3-mediated necroptosis252,276,
and these inhibitions have been observed repeatedly in different cell lines. Elegant studies
have demonstrated that loss of function mutations to these viral inhibitor proteins results
in the loss of specific anti-death functions, to then allow MCMV-infected cells to die
exclusively through that specific pathway. Thus, simultaneous inhibition of death
pathways is required for effective survival of the virus. We utilized MCMV’s capacity to
alter cell death to further study intrinsic cell death in DKO TEC. To test whether the
MCMV’s cell death inhibition capabilities could alter TEC survival following deathinducing treatments, we measured the viability of MCMV-infected TEC post- IL-1β +
IFN-γ treatment using MTT assays. Propagation of wild-type K181 BAC MCMV strain,
crude stock harvesting, and TEC infection were performed as described in methods255.
IL-1β and IFN- γ were used to induce intrinsic apoptosis in uninfected and MCMVinfected TEC. Uninfected TEC showed expected decreased viability with IL-1β + IFN-γ
treatment (viability 57.0 ± 9.6 in uninfected treated wild type TEC vs. 100 in uninfected
untreated wild type TEC, n=3, p=0.046; 39.3 ± 3.77 in uninfected treated RIPK3-/- TEC
vs. 100 in uninfected untreated RIPK3-/- TEC, n=3, p=0.0038; 29.3 ± 0.3 in uninfected
treated DKO TEC vs. 100 in uninfected untreated DKO TEC, n=3, p<0.0001, Figure 12).
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Importantly, with MCMV infection, we observed near complete salvage of viability in
response to IL-1β + IFN-γ treatment in the cell lines (viability 85.0 ± 9.3% in infected
treated wild type TEC vs. 57.0 ± 9.6% in uninfected treated wild type TEC, n=3,
p=0.025; 87.3 ± 3.53% in infected treated RIPK3-/- TEC vs. 39.3 ± 3.8% in uninfected
treated RIPK3-/- TEC, n=3, p=0.022; 53.7 ± 3.93 in infected treated DKO TEC vs. 29.3 ±
0.3 in uninfected IL-1β + IFN-γ treated DKO TEC, n=3, p<0.0001). Interestingly,
MCMV infection decreased the overall viability of DKO TEC (viability 64.0 ± 4.0% in
infected untreated DKO TEC vs. 100 in uninfected untreated DKO TEC, n=3, p=0.012),
which was not observed in wild type or RIPK3-/- TEC. In summary, our data suggests that
MCMV infection improves the survival of TEC from IL-1β + IFN-γ induced intrinsic
apoptosis.
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Figure 13. MCMV abrogates IL-1β /IFN- γ induced intrinsic apoptosis in TEC
Ai-iii. TEC were cultured as described in the methods. Wild type, RIPK3-/-, and DKO
TEC were treated with combination of 4 ng/mL IL-1β and 120 ng/mL IFN- γ for 24
hours in serum-free media in absence and presence of MCMV infection to induce
intrinsic apoptosis. Cell viability was measured and quantified using MTT assay
analyses. Figures represent one of three independent experiments, which showed the
same results. (n=3, *: p < 0.05, **: p<0.01, ****: p<0.0001, Two-Way ANOVA).
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3.9 Pro-inflammatory activation of TEC is augmented in the
absence of necroptosis and extrinsic apoptosis
We hypothesized that in absence of RIPK3-mediated necroptosis and caspase-8-mediated
apoptosis, DKO TEC may demonstrate enhance responses related to NF-κB signaling. As
mentioned previously, renal IRI results in the infiltration of immune effector cells into the
renal parenchyma, thereby causing the activation of and up-regulation by TEC of diverse
pro-inflammatory chemokines and cytokines28. TNFα277, IFN-γ278, and HMGB-153 are
prominent molecules that participate in IRI by activating TEC. TEC up-regulate proinflammatory NF-κB signaling upon activation, leading to repeated cycles of
inflammation that are detrimental to the graft survival (Figure 3). These pathways of
activation would be expected to be intact in TEC despite loss of caspase-8 or RIPK3, and
indeed may be enhanced in cells that are exposed to stimulation, yet unable to die. We
therefore tested the expression of selected pro-inflammatory chemokines and cytokines
produced by TEC. MCP-1, RANTES, and IL-6 have been well reported to exacerbate
IRI. TEC were treated with 30 ng/mL TNFα + 30 ng/mL IFN-γ, 500 ng/mL of LPS, and
1 µg/mL of HMGB-1 for 24 hours, and RT-PCR was performed as described. This
treatment can induce cell death but is much less than what we have demonstrated with
IL-1β and IFN- γ combination that triggers intrinsic apoptosis. We used Two-way
ANOVA analyses to assess differences in the cell lines. Treatments induced upregulation of MCP-1 (Figure 13Ai-iii), RANTES (Figure 13Bi-iii), and IL-6 (Figure
13Ci-iii) mRNA in TEC, but notably the greatest increase was observed in DKO TEC
(Figure 13D). These results confirm that DKO TEC retain the capacity to express proinflammatory chemokines and cytokines. Furthermore, in the absence of necroptosis and
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extrinsic apoptosis, TEC appear to have enhanced pro-inflammatory responses following
activation.
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Figure 14. Pro-inflammatory response is enhanced in TEC in the absence of
necroptosis and extrinsic apoptosis
TEC were cultured as described in the methods. Wild type, RIPK3-/-, and DKO TEC
were treated with 30 ng/mL TNFα + 30 ng/mL IFN-γ, 500 ng/mL of LPS, and 1 µg/mL
of HMGB-1 for 24 hours in serum-free media. mRNA levels of Ai-iii. MCP-1, Bi-iii.
RANTES, and Ci-iii. IL-6 were measured by RT-PCR as described in the methods. βactin was used as loading control. D) Table of interaction factor significance from
Two-way ANOVA analysis. Figures represent one of three independent experiments
which show the same results (n=3, **: p<0.01, ***: p<0.001 ****: p<0.0001, TwoWay ANOVA).
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Chapter 4

4

Discussion

4.1 Overview of results
The foundation of the majority of work in this thesis follows the observation that the loss
of two regulated cell death pathways, which are known to independently reduce renal
IRI, failed to have an additive benefit in IRI. Indeed, there was a trend to worsened renal
function with IRI in DKO mice. While the kidney is composed of many cell types, TEC
represent 75% of the parenchymal cells and are the cells that are most active in kidney
function as well as being the primary target in most renal transplant rejection. In addition
to primary cultured cells, we utilized the immortalized wild type NG, RIPK3-/-, and DKO
TEC cell lines for in vitro experiments in these studies that were designed to test the
impact of removal of two cell death pathways on residual function and survival (Figure
7). In this sense, the TEC represents most but not all the responsible cells involved in IRI.
Further studies would need to also include endothelial cells. We have shown basal level
cell surface expressions of TNFR-1, TNFR-2, FAS, DR 5, TLR 2, and TLR 4 do not vary
between cell types, nor do receptor levels change in response to activation with TNFα
and IFN-γ in TEC (Figure 8). We have found that TEC also do not exhibit an increased
sensitivity to CHX + TNFα and LPS (Figures 9) to cause death, and indeed TEC are
generally resistant to death. However, we showed that DKO TEC exhibit enhanced
sensitivity to IL-1β + IFN-γ induced intrinsic apoptosis, which could be recovered by the
addition of BIP (Figure 10). We also noted up-regulation of caspase-9 and caspase-3
activity in response to IL-1β + IFN-γ treatment in all cells but was maximal in DKO TEC
(Figure 10). DKO TEC showed up-regulation of mRNA levels of BAX and BAK (Figure
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11). Following infection with MCMV, which inhibits cell death programs within cells,
TEC showed near-complete abrogation of death (Figure 12). Lastly, mRNA expression
levels of pro-inflammatory MCP-1, RANTES, and IL-6 were up-regulated in all TEC but
was maximal in DKO TEC treated with TNFα + IFN-γ, LPS, and HMGB-1 as compared
to wild type or RIPK3-/- TEC (Figure 13). The absence of RIPK3-mediated necroptosis
and caspase-8-mediated extrinsic apoptosis thus favours BAX-mediated intrinsic
apoptosis in TEC and promotes the expression of pro-inflammatory NF-κB signaling. IRI
continues to be a major early cause of organ injury in many clinical scenarios including
sepsis-induced hypotension and in transplantation where the donor organ is invariably
subjected to temporary ischemia. While there may be clinical benefit in targeting
apoptosis and necroptosis, the data in this thesis suggests additional targeting of renal
allograft-specific BAX, caspase-9, caspase-3, and NF-κB might be necessary to
maximize protection of the donor organ in renal transplantation.

4.2 Cell death and allograft rejection
From organ extraction to post-transplantation IRI, TEC are susceptible to cell death and
injury that leads to attenuated graft function and potentially organ failure. Several factors
contribute to this process, and there must be still undiscovered mechanisms that inflict
critical damage to grafts. IRI is of course a prime example, but being complex and
multifactorial, it has been difficult to adequately prevent IRI. One important aspect of IRI
is the induction of many forms of cell death, which include but are not limited to
apoptosis and regulated forms of necrosis such as necroptosis and ferroptosis.
Collectively, each of these pathways contributes to overall dysfunction of the organ, as
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well as compromising the regenerative capacity of the graft. If exceeded, permanent
organ dysfunction may occur and indeed the most important predictor of renal transplant
survival is donor age. This might be because cell death in an aged organ that has limited
regenerative capacity likely has a different implication than cell death in a young organ.
During IRI, TEC and other parenchymal cells of renal allografts are subjected to death by
inflammatory cytokines and infiltrating immune cells, resulting in activation of host
immune responses279. The specific forms of cell death are critically important to graft
survival as the magnitude of immune responses during IRI can greatly influence early
rejection and thus, graft survival. Apoptosis and necroptosis are distinctive forms of
regulated death in TEC that orchestrate different immune responses to accelerate graft
rejection.
Apoptosis has long been considered a prototypical form of programmed cell death, and it
has been comprehensively studied using diverse research models in oncology,
developmental biology, and transplantation models280,281. Apoptosis results in formation
of ‘shrinking’ Annexin-V positive cells that are ‘cleaned up’ by phagocytes, leading to
minimal inflammatory consequences. Indeed within the kidney, KIM-1 bearing TEC act
as the primary intrarenal phagocytes to remove phosphatidylserine (PS) bearing debris
from all forms of cell death282. Because of its non-immunogenic characteristics, apoptosis
was once considered as not participating in worsening clinical transplantation, but
research over the past decade has proven otherwise. A recent study has shown proximal
TEC undergoing apoptosis during IRI express an “eat me” molecule, KIM-1, which
permits efferocytosis amongst TEC282, as well as infiltration of phagocytes into renal
tubules283,284. Furthermore, caspase-8 silencing or transgenic overexpression of the
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caspase-8 inhibitor c-FLIP protected TEC against TNF−α induced apoptosis in vitro and
renal IRI in vivo19,285. Apoptotic cells not immediately cleared by the immune system
may undergo secondary necrosis, resulting in plasma membrane rupture and release of
intracellular contents that act as DAMPs on neighbouring cells to promote further
inflammation and death280. Interestingly, while silencing caspase-8 has proven to be
beneficial in renal IRI, it led to reduced allograft survival135. While these findings
highlight the important role apoptosis plays in renal IRI, they also emphasize the complex
biology and the possibility of harm from strategies that do not take into account the interrelation of these cell death pathways. In this case, our observation that the combined loss
of apoptosis and necroptosis did not improve IRI in vivo, immediately suggests that there
may be a relationship to other forms of cell death.
Contrary to apoptosis, until recently necrosis was thought to be an unregulated, “messy”
form of cell death caused by sudden trauma. Studies have found that TNF superfamily
receptors TNFR1 and Fas can induce a downstream transduction cascade of necrosis as
well as apoptosis when stimulated148,286,287, revealing a novel form of controlled,
programmed necrosis termed necroptosis which is controlled by interactions of caspase8, RIPK1, and RIPK3192. Necroptosis cannot be distinguished from unregulated necrosis
or secondary necrosis based on morphology, as the pathways converge on common ‘endpoint’ features such as rupture of plasma membrane integrity and release of cytoplasmic
contents147, which can start a devastating inflammatory cascade152. As expected, a recent
study proved that knocking out RIPK3 mediated necroptosis to prevent inflammatory
outcomes granted significant benefits in kidney function and reduced ATN in renal IRI
model135. In this model, inflammation and rejection are attenuated but not completely
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eliminated as evidenced by the infiltration of RIPK3-/- transplanted kidneys, and the
detection of HMGB-1 in late samples. This would suggest that other forms of cell death
exist in even long-term transplants, and the likely candidates remain- extrinsic and
intrinsic apoptosis. In the current study, clearly the removal of extrinsic apoptosis and
necroptosis sensitized cells to intrinsic apoptosis. While we were examining IRI as a
model in this study, it would be intriguing to suggest that intrinsic apoptosis would also
play a role in transplant outcomes. In preliminary studies of transplantation using DKO
donor kidneys, this seems to be the case. Similarly, it would be of interest if intrinsic
apoptosis inhibition could attenuate the late injury and HMGB1 release observed in the
transplants with RIPK3-/- kidneys.
In our study, we investigated potential benefits granted by deletion of both caspase-8 and
RIPK3 in renal IRI using RIPK3-/- caspase-8-/- DKO mice. Here, we report that RIPK and
caspase-8 deficiency does not grant additional benefits compared to RIPK3 deficiency
alone, as DKO mice showed slight increase in serum creatinine levels and ATN scores
were nearly identical (Figure 6). These in vivo data might indicate an over-compensatory
mechanism by TEC where the absence of necroptosis and extrinsic apoptosis is
negatively affecting kidney function without inducing ATN, suggesting presence of
programmed, non-inflammatory cell death. Recently it has been reported in abstract form
that IL-10 production by double negative CD3+ CD4- CD8- DNT cells have an
attenuating effect on renal IRI288. As the DKO mice used in this study show an expansion
of DNT cells that results in splenomegaly and lymphadenopathy, it may be that the
magnitude of intrinsic apoptosis injury we observed was muted by the presence of these
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cells. It would be of interest to test the IL-10 production in these DNT cells and perhaps
use a model in which the host cells were normal, and only the kidney was a ‘DKO.’

4.3 Absence of RIPK3 and caspase-8 sensitizes TEC to
BAX-mediated intrinsic apoptosis
Since there were no additional benefits granted on DKO mice compared to RIPK3-/mice, we deduced that alternate forms of cell death might be enhanced with perturbations
of necroptosis and extrinsic apoptosis. We confirmed that both primary and immortalized
DKO TEC do not undergo apoptosis nor necroptosis induced by CHX + TNFα or LPS
treatment (Figure 9), as expected in the absence of RIPK3 and caspase-8. It is also
interesting to note that the CHX + TNFα and LPS treatments did not induce substantial
amount of death, demonstrating the TEC have endogenous mechanisms of protection
including osteopontin production, cellular FLICE-like inhibitory protein (cFLIP), and
various inhibitor of apoptosis proteins (iAPs).
Many subtypes of intrinsic apoptosis have been described, with different functions and
significance ranging from a role in retinoblastoma as well as p53-dependent apoptosis
that controls growth development triggered in response to stress (hypoxia, radiation)289291

. There is surprisingly little known about the role of intrinsic apoptosis in renal IRI, but

limited studies have suggested intrinsic apoptosis contributes to IRI-induced graft
damage292. Nephrotoxicity from drugs such as cisplatin is partly due to BAX and
caspase-9 mediated intrinsic apoptosis of TEC293,294. In DKO TEC, the caspase-9
dependent intrinsic apoptosis pathway is intact, so we decided to investigate whether
augmentation of intrinsic apoptosis was present in DKO TEC.
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Intrinsic apoptosis was triggered in vitro in immortalized wild type, RIPK3-/-, and DKO
TEC using combination of IL-1β and IFN-γ 274, and BIP was added to test whether the
death induced was BAX-mediated apoptosis295,296. While we showed DKO TEC are
sensitized to IL-1β + IFN-γ induced intrinsic apoptosis, BIP was not able to achieve
complete rescue in the TEC. MTT and Sytox Green assays are limited in the ability to
identify specific forms of cell death, although the uptake of Sytox would suggest
membrane permeability as might be the case with late apoptosis and secondary necrosis.
Caspase-9 and caspase-3 assays helped to more conclusively determine the presence of
intrinsic apoptosis in TEC and that DKO TEC appear to die almost exclusively through
intrinsic apoptosis, whereas wild type and RIPK3-/- TEC as expected, die by other
pathways as well. Caspase-8 is capable of activating pro-caspase-9 through SEPD
domain cleavage297, and a previous study has shown IFN-γ can mediate activate FAS and
caspase-8 dependent apoptosis in TEC285. With BAX inhibition, caspase-8 could be
directly activating caspase-9, hence explaining the ineffectiveness of BIP treatment we
observed in immortalized wild type and RIPK3-/- TEC.
IL-1β is a pro-inflammatory cytokine secreted by TEC and infiltrating immune cells. IL1β expression rapidly increases during renal IRI298 contributes to inflammation in renal
allografts in conjunction with other cytokines299, triggers cytochrome c release from the
mitochondria and activates caspase-9 activity. Also, IFN-γ induces BAD
dephosphorylation and caspase activation300,301. NLRP3-/- mice that are unable to produce
IL-1β and inflammasomes showed better survival and function post IRI302, highlighting
the prominent negative impact resulting from IL-1β and other inflammasome related
stress in renal IRI. Interestingly, a recent study induced several different forms of
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intrinsic apoptosis on wild type, RIPK3-/-, and DKO thymocytes using drugs and stress
stimuli and reported no sensitivity differences192, suggesting enhanced BAX-mediated
intrinsic apoptosis may be a phenotype unique to TEC of DKO mice.
We used RT-PCR analyses to measure basal level transcriptional differences of BCL-2
family genes in immortalized wild type, RIPK3-/-, and DKO TEC. Indeed, we found
greatest up-regulation of pro-apoptotic BAX, BAK, and BAD in DKO TEC (Figure 11).
However, it remains to be seen whether the transcriptional up-regulation of pro-apoptotic
genes correlate to translational level, making protein analysis such as Western blotting
necessary. Previous studies have observed an increase in BAX and BAK in both mRNA
and proteins levels in rat proximal TEC post-IRI212,213, supporting our results and
validating the role of intrinsic apoptosis in renal IRI. Interestingly, one study showed
acidic pH could inhibit BAX-dependent, caspase-9 mediated apoptosis in ATP-depleted
TEC through disruption of apoptosome-mediated caspase-9 activation303. Acidosis is an
inherent outcome of organ ischemia as cells resort to anaerobic metabolism in response to
oxygen and glucose deprivation, leading to increased lactic acid production and thus a
subsequent decrease in pH304,305. Therefore, intrinsic apoptosis of TEC could be a
prominent reperfusion-specific mechanism.
While loss of caspase-8 and RIPK3 enhances BAX-mediated intrinsic apoptosis and
inhibition of BAX through BIP rescued TEC death (Figure 10), we do not have
conclusive in vivo renal IRI data confirming the presence of heightened intrinsic
apoptosis in DKO mice. Immunohistochemistry staining of caspase-9 on DKO kidney
sections or in situ injection of BIP in DKO kidneys and observing outcomes in renal IRI
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model would solidify our findings, but unfortunately we were not able to perform these
reliably.

4.4 Activation of death receptors on TEC can promote
inflammation
The intense inflammatory cascade upon reperfusion remains a recurring issue during
kidney transplantation for its contribution to delayed graft function and promoting
adaptive immune responses28,306,307. The early stage inflammatory responses can severely
compromise the survival of allografts. Among the diverse factors that contribute to IRI,
such as IL-6, contribute to the general inflammatory state. Others, such as TNFα, IFN-γ
and IL-1β contribute to death307 and chemokines MCP-1 and RANTES contribute by
increasing the infiltration by effector cells. These can be produced by the effector cells
and by TEC75,76,96,99. Innate immune responses, including but not limited to PMN,
macrophage infiltration, and NK cell priming, following the secretion of proinflammatory cytokines and chemokines are hallmarks of renal IRI308. While we were not
able to reproduce the complex in vivo situation, in this study, we treated TEC with TNFα
+ IFN-γ, LPS, and HMGB-1 to simulate the receptor activation-induced inflammation
from IRI in vitro and used RT-PCR analysis to measure expression of IL-6, MCP-1, and
RANTES at the mRNA transcriptional level.
TNFα and IFN-γ are classic inducers of pro-inflammatory NF-κB signaling, and it has
been shown TNFα and IFN-γ contribute to inflammatory damage by up-regulation of
many chemokines and cytokines during renal IRI31,278. In this study, TEC were exposed
to murine TNFα and IFN-γ to ‘mimic’ the environment of IRI, using LPS to activate TLR
and as a positive control. TEC showed up-regulation of IL-6, MCP-1, and RANTES, in
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response to the treatments, with the DKO TEC showing a remarkable difference (Figure
13) compared to wild type or RIPK3-/- TEC. This data suggest that in the absence of
caspase-8 and RIPK3, DISC complex formation can proceed only to pro-inflammatory
signaling (Figure 4) thus promoting significant inflammation. We, however, were not
able to support the in vivo upregulation with in vivo increases in infiltration, as the total
counts could only identify cells such as PMN, which can be counted in H&E stained
samples. More specific phenotyping of cells would require considerable additional work,
which was not done in this thesis.
HMGB-1 is an intracellular molecule that acts as a DAMP once released from necrotic
cells61. Released HMGB-1 can bind to TLR 2, 4, 9, and RAGE of neighbouring TEC and
immune cells to promote the production of chemokines and cytokines shown to
participate in IRI and during graft rejection58,60,309. Several forms of HMGB-1 have been
identified310,311. The reduced form of HMGB-1 is released by necrotic cells and possesses
highly immunogenic capabilities, whereas apoptotic cells release oxidized HMGB-1 that
has minimal immunogenicity312. In this study, we observed an increase in IL-6, MCP-1,
and RANTES expressions of wild type and RIPK3-/- TEC in response to recombinant
murine HMGB-1. Interestingly, DKO TEC showed down-regulation of MCP-1 and IL-6
against HMGB-1 (Figure 13). This is a somewhat disparate finding, as previous studies
have shown that HMGB-1 exerts its pro-inflammatory functions by inducing upregulation of MCP-1, RANTES, and IL-6 and maximal protection was observed in renal
IRI when HMGB-1 was unable to interact with kidney TLRs 53,59,313. There are no known
anti-inflammatory functions of HMGB-1 in solid organ transplants, although
immunosuppressive and anti-proliferative roles of HMGB-1 have been identified in
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certain T cell subgroups314,315. This could be a new finding that DKO TEC in fact show
anti-inflammatory responses against HMGB-1. It would be interesting for future studies
to investigate whether HMGB-1 could have anti-inflammatory and immunosuppressive
functions in other conditions.
Another intriguing finding was that basal levels of MCP-1, RANTES, and IL-6 were
significantly higher in DKO TEC compared to wild type or RIPK3-/- TEC. While it may
have been expected that DKO TEC could exhibit over-activation in response to proinflammatory treatment, the response in resting cells merits consideration of the normal
‘outside-in’ signals that cells obtain to maintain homestasis. Nonetheless, the increased
expression of chemokines and cytokines may have contributed to a reduced benefit in the
DKO mice with IRI (Figure 6). Kang et al (2013) used Itgax-Cre system to achieve
specific deficiency of caspase-8 in RIPK3-/- mice that mimics our DKO mouse model.
Interestingly and in contrast to our results, they reported that LPS treatment downregulated pro-inflammatory TNFα and IL-1β at protein level in dendritic cells316. These
findings suggest that different cell types with similar genetic deletions respond differently
to similar treatments, leading to different result. It is now known that Nec-1 has many
off-target effects317.
Clearly, one of the limitations of our studies was that in vitro treatments would not fully
simulate the in vivo situation of IRI. We also used mRNA analyses and it remains to be
seen whether the observed up-regulation of chemokines and cytokines at transcriptional
level correlates at translational level. Thus, future studies focusing on protein and in vivo
expression of chemokine and cytokines in renal IRI should strengthen our data.
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Furthermore, performing immunohistochemistry staining of macrophage and NK cell
infiltrates may support that the DKO TEC enhance chemotaxis in vivo.
TNFα + IFN-γ treatment did not induce any changes in the cell surface death receptor
expression levels (Figure 8). Cells normally respond to TNFα + IFN-γ activation by upregulating surface death receptor expressions both in vitro91,318 and in vivo319,320. This
result may suggest that different cells respond to different concentrations of cytokines,
and perhaps TEC require higher amounts to change cell surface death receptors. Also,
this indicates that RIPK3 and caspase-8 do not participate in receptor shuttling as DKO
TEC showed similar basal level receptor expressions.
Another interesting finding of our death receptor results is that TEC show high basal
level expression of DR 5. DR 5 is a family of TNF receptor superfamily, and serves as a
receptor TRAIL321,322. DR5 is one of the best-characterized receptors in oncology due to
its roles in tumour cell apoptosis. Most cancer cells down-regulate DR 5 expression to
minimize vulnerability to apoptosis. Several cancer therapeutic drugs act to up-regulate
DR5 expression of the cancer cells and sensitizes them to TRAIL-mediated
apoptosis323,324. While the knowledge of DR 5 and TRAIL in cancer research is vast, our
current understanding of their potential role in renal IRI is limited. TRAIL activation of
DR 5 is known to induce caspase-8-dependent apoptosis. As mentioned before, caspase-8
also inhibits RIPK3-mediated necroptosis and promotes apoptosis. In acidic pH
conditions however, TRAIL was found to induce a form of necrosis325. Surprisingly, this
was dependent on caspase-8326, revealing yet another surprising role of caspase-8. During
renal ischemia, TEC are under hypoxic stress due to lack of oxygen and resort to
anaerobic metabolism that leads to lactic acid accumulation and subsequent acidic pH
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environment inside the allograft327,328. With high level of DR5 of TEC in conjunction
with acidic pH during ischemia, it is possible that TEC similarly undergo DR 5 mediated
necrosis. Future studies investigating the importance of TRAIL and DR 5 in renal IRI
could reveal additional mechanism of TEC death.
Finally, innate immunity has been increasingly associated with acute phase damage posttransplantation82,329,330. Two key components, namely TLR 2 and TLR 4, have been
extensively studied for their prominent roles in triggering pro-inflammatory responses
from TEC during renal IRI54,55,331,332. With high basal level expression of TLR 2 and TLR
4, physiological stress during IRI could contribute to TEC activation.

4.5 MCMV influences cell death pathways
Human CMV infection has been the most common and challenging viral infection in
solid organ transplantation. Previous studies prior to antibiotics, have shown that
symptomatic CMV infection can occurs in up to 60% of renal transplant recipients333.
Ganciclovir treatment remains the most widely used prophylactic strategy334, but it is
expensive335, often only delays rather than prevents the onset of the CMV disease336,337,
and may promote viral resistance338. Symptoms of CMV infection include episodic fever,
fatigue, and abdominal pain. CMV can infect broad range of cells and tissues, and
eventually cause organ failure and death339. Moreover, CMV infection
immunosuppresses patients, exposing them to other life threatening pathogens340,341.
Murine CMV encodes various cell death inhibitor proteins that are made during the
immediate early phase of infection. Due to species differences however, MCMV cannot
circumvent immune defense of humans, which makes humans resistant to MCMV
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infection. Even with large exposure, MCMV is quiescent in human cells and replication
is at a level that does not induce pathological symptoms255,342. In our study, we infected
immortalized TEC with wild-type K181 BAC strain of MCMV253 and tested whether
MCMV generated death inhibitor proteins conferred survival benefit on TEC under
death-inducing stimuli. From MTT assay results, we saw near-complete salvage of
MCMV-infected TEC treated exposed to IL-1β + IFN-γ (Figure 12). This was consistent
with previous findings that MCMV can inhibit intrinsic apoptosis via BAX and BAK
inhibition through vMIA and vIBO, respectively198,343. Interestingly, MCMV was more
effective in restoring cell viability across all three cell lines compared to BIP, which was
the most effective in DKO TEC (Figure 10). This suggests DKO TEC may undergo
BAX-mediated intrinsic apoptosis exclusively. Wild type and RIPK3-/- TEC that may be
undergoing other forms of cell death would be expected perhaps to be more responsive to
MCMV salvage. We also saw that MCMV infection was not able to salvage survival in
DKO TEC to levels observed with wild type or RIPK3-/- TEC. This may suggest that
other forms of cell death remain in DKO TEC when RIPK3, capsase-8, BAX, and BAK
are all simultaneously inhibited. Since we used MTT assays to measure cell viability, it is
impossible to clearly identify what type of cell death the TEC are undergoing.
At this time, our interest in MCMV is as a tool to understand cell death pathways, as it is
remarkable that this virus has exploited an ability to control all known forms of regulated
cell death in TEC. However, as the MCMV genome is very well characterized, it may be
possible to manipulate this virus to allow localization to renal allografts and control cell
death for a limited period of time in donor organs prior to transplant, i.e. during IRI. A
previous study has shown that IRI-induced TNF-mediated NF-κB signaling and ROS
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production activates the enhancer region of immediate-early phase promoter region of
HCMV344. IRI could induce the production of CMV-derived cell death inhibitor proteins
if infection could be targeted and limited. Obviously this sort of viral based strategy
would require extreme caution in the clinical scenario.

4.6 Renal transplants, immunosuppressive and cell death
drugs
Over the past several decades, acute rejection and survival rates of renal allografts have
been improving; this has been mainly attributed to increased first-year survival among
patients345. Despite the advances in the short-term survival, long-term survival remains as
the most significant challenge, as there has not been a substantial improvement in longterm outcomes in kidney transplants124,346. This compounds the current problem of having
too few organ donors, as recipients with premature transplant failure return to the
transplant waiting list, along with patients who have never received a previous transplant.
It remains unclear what contribution early damage makes to reduced long-term graft
survival, but it is intuitive that modifying early injury is not likely to harm, and more
likely to improve early and perhaps late graft function. Therefore, this study was focused
on IRI, which is an invariable and early consequence of organ donation and is amenable
to intervention. Strategically, as this laboratory is focused on regulated cell death, we
were interested in attenuating multiple forms of cell death, in order to attenuate IRI.
IRI orchestrates a cascade of innate and adaptive immune responses that exacerbate
allograft damage by stimulating cellular rejection, antibody production, and immune cellmediated killing that results in parenchymal cell death. Collectively or individually, these
compromise allograft survival43,126,279. We have shown that simply blocking both
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caspase-8 and RIPK3 to eliminate extrinsic apoptosis and necroptosis, respectively, did
not have the intended effect of reducing IRI more than what we had observed by single
pathway elimination. This is therefore unlikely to be effective as a strategy in transplants
and indeed in our preliminary results using DKO donor kidneys, there was no benefit. It
may be that the enhanced injury from augmented intrinsic apoptosis may be even more
apparent in transplant recipients having normal circulating T cells, in contrast to what we
observed in the DKO mice. Recent reports have shown that CD3+ CD4- CD8- DNT cells
are found within the kidney post-IRI and that kidney resident DNT cells up-regulate antiinflammatory IL-10 and IL-27, thus suggesting a potential protective role for these cells
in IRI288. Importantly, the DKO mice we used develop lymphadenopathy due to a high
number of spontaneously generated DNT cells192. These may have actually attenuated the
amount of injury we observed with IRI. Similarly, it would be interesting to see whether
DNT cells from DKO mice might mitigate intrinsic apoptosis injury with adoptive
transfers to other mice in vivo.
Current immunosuppressive drugs act as double-edged sword, as the use of tacrolimus
and sirolimus disables T lymphocyte function and proliferation yet can induce
nephrotoxicity through fibrosis and perhaps cell death347,348. With recent advances in
elucidating mechanisms of cell death, specific forms of cell death during early stages of
transplantation may generate alternative strategies to alter immune responses, i.e. through
reduction of cell death and innate immunity. At present, there are no clinically approved
pharmacological inhibitors of cell death that could be administered along with
immunosuppressive therapies, although Nec-1 has considerable potential at the
preclinical stage. All of these agents could be considered for organ preservation solutions.
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While Nec-1 can be used to target necroptosis along with caspase inhibitors to target
apoptosis, it may be possible to tailor strategies that affect intrinsic apoptosis more than
extrinsic apoptosis. While we administered BIP in vitro and this could be given in vivo, a
potential side effect of intrinsic apoptosis inhibition might be up-regulation of ferroptosis,
a newly described form of regulated necrosis dependent on iron349. Contrary to intrinsic
apoptosis requiring VDAC opening, ferroptosis needs ‘closed’ VDAC350, which can be
achieved using erastin to block VDAC opening350. A recent study has shown that TEC
can undergo synchronized, rapid, post-ischemic ferroptosis, which can be inhibited by
ferrostatins137. Due to the nature of intrinsic apoptosis and ferroptosis that depend on
opposite states of VDAC, future studies would need to investigate effects of BIP
inhibition in vivo, and the relation of intrinsic apoptosis to ferroptosis in renal IRI. BIP, in
conjunction with Nec-1, could potentially become an effective combination to improve
graft survival in patients.

4.7 Conclusion
In this study, we report for the first time that the loss of two forms of regulated cell death,
namely RIPK3 mediated necroptosis and caspase-8 mediated apoptosis, which are known
to independently reduce renal IRI, failed to provide a benefit in IRI, when combined.
This was not related to altered surface expression of death receptors on TEC, but is
correlated to enhanced BAX dependent, caspase-9 mediated intrinsic apoptosis. The
mechanism is unknown but may be related to the loss of control of intrinsic apoptosis by
caspase-8 and RIPK3 or the downstream proteins they control. We also show that DKO
TEC can become ‘over-activated’ in response to treatments with cytokines and DAMP,
leading to up-regulation of pro-inflammatory cytokines and chemokines. This has
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considerable implications in clinical strategies that target cell death in IRI and
transplantation as multiple pathways may require inhibition for effect. Furthermore, we
demonstrate for the first time that MCMV infection completely abrogates intrinsic
apoptosis in TEC. Therefore, inhibition of necroptosis, extrinsic apoptosis, and intrinsic
apoptosis may be necessary to confer maximal protection in IRI and in renal allografts.
Inhibition of pro-inflammatory NF-κB signaling also must be taken into consideration to
minimize repeated cycles of inflammation cascade that could persist and lead to graft
rejection.

4.8 Future directions
Future studies will be needed to fully investigate the significance and importance of
caspase-9 mediated intrinsic apoptosis in IRI in vivo, which will consider more than TEC
responses. Drug strategies may be designed to target intrinsic apoptosis-related proteins
such as caspase-9, BAX, and BAK in an organ-specific manner along with targeting
necroptosis and caspase-8 apoptosis. This will be critical to develop applicable treatments
in renal transplantation. The remarkable ability of CMV to block specific forms of cell
death may be exploited in a clinical strategy, but will require caution in targeting organs
in isolation from the recipient and in a time limited form. Finally, these studies need to be
extended to transplantation models that add alloinjury to the ischemic injury. These
ultimately are the major goal of this work.
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